document incorporate reference incorporate scheringplough corporation proxy iii statement annual meeting shareholder april table content item business item property item legal proceeding item submission matter vote security holder item market registrant common equity relate stockholder matter item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item principal accountant fee service item exhibit financial statement schedule report form signatures global note global note letter agreement employment agreement amendment supplement employment agreement supplement employment agreement operation management team incentive plan cash longterm incentive plan longterm performance share unit incentive plan transformational performance share program distribution agreement computation ratio earning fix charge code ethic subsidiary consent deloitte touche llp power attorney certification certification certification certificationtable content item business term scheringplough company refer scheringplough corporation subsidiary indicate context scheringplough corporation incorporate trademark indicate capital letter property license promote distribute scheringplough corporation subsidiary relate company subsidiary scheringplough engage discovery development manufacturing marketing pharmaceutical product worldwide discovery development effort target field human health occasionally application field animal health result effort company view animal health application mean maximize return investment discovery development company operate primarily prescription pharmaceutical marketplace appropriate company seek future seek regulatory approval switch prescription product overthecounter otc status mean extend product life cycle way otc marketplace mean maximize return investment discovery development november company announce formulation claritin brand nondrowsy allergy product approve original prescription strength fda otc medicine treatment allergy company launch otc claritin united states december december compete otc loratadine product launch united states quarter company begin face additional privatelabel competition otc claritin line nonsedate antihistamines initial day period exclusivity expire otc generic competitor company continue market clarinex desloratadine tablets treatment allergic rhinitis combine indication seasonal allergic rhinitis indication perennial allergic rhinitis treatment chronic idiopathic urticaria hive unknown cause ability company capture maintain market share clarinex otc claritin market depend number factor include additional entrant market allergy treatment clinical differentiation clarinex allergy treatment perception extent differentiation marketplace pricing differential otc claritin clarinex allergy treatment generic otc loratadine erosion rate otc claritin clarinex sale entry additional generic otc loratadine product brand secondgeneration antihistamine switch prescription otc status clarinex experience intense competition prescription allergy market prescription allergy market shrink otc switch claritin december company implement new marketing effort address market share performance clarinex table content switch claritin otc status introduction compete otc loratadine result rapid sharp material decline claritin sales united states company result operation sale prescription claritin product million percent company consolidated global sale billion percent sale clarinex united states abroad materially adversely affect presence generic otc loratadine otc claritin light factor describe management believe company december introduction otc claritin introduction compete otc loratadine product december additional entrant generic otc loratadine product market rapid sharp material adverse effect company result operation likely continue indeterminate period time company merck inc merck agreement jointly develop market zetia ezetimibe oncedaily monotherapy coadministration zetia statins ezetimibe oncedaily fixedcombination tablet simvastatin zocor merck cholesterolmodifye medicine agreement involve development marketing oncedaily fixedcombination tablet contain claritin singulair singulair merck oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis january scheringploughmerck pharmaceutical report result phase iii clinical trial fixedcombination tablet contain claritin singulair demonstrate sufficient add benefit treatment seasonal allergic rhinitis october merckscheringplough pharmaceutical announce fda approve zetia ezetimibe use statin treatment elevate cholesterol level march company announce ezetimibe ezetrol market europe successfully complete european union mutual recognition procedure mrp completion mrp process member states iceland norway grant national marketing authorization unify labeling ezetrol ezetrol launch international market agreement generally provide equal sharing development cost copromotion approve product company united states country world japan japan agreement exist general copromotion provide company provide equal physician marketing effort company bear cost sale force marketing product general agreement provide venture operate virtual mode maximum degree possible rely respective infrastructure company company agree share certain cost cost limited portion cost manufacturing cost specialty sale force certain specially identify promotion cost note company incur substantial cost sell cost reflect equity income cholesterol joint venture bear entirely company agreement provide jointly own facility product result collaboration manufacture facility own merck company table content additional prescription product sell company include asmanex celestamine foradil nasonex polaramine proventil allergyrespiratory caelyx cedax ethyol eulexin garamycin intron pegintron rebetol ribavirin remicade temodar anti infective anticancer diprolene diprosone elocon lotrisone quadriderm valisone dermatological integrilin kdur nitro dur cardiovascular celestone diprospan subutex temgesic pharmaceutical pegintron rebetol combination therapy hepatitis contribute substantially sale fourth quarter compete pegylate interferonbased combination product include brand ribavirin receive regulatory approval major market include united states overall market share intron franchise decline sharply reflect new market competition management believe ability pegintron rebetol combination therapy maintain market share continue adversely affect new competition hepatitis marketplace animal health product include cepravin nuflor antimicrobials banamine zubrin nonsteroidal antiinflammatorie ralgro growth promotant implant otomax otic product broad range vaccine specie parasiticide suture bandage nutritional product foot care otc sun care product include clear away wart remover scholl foot care product lotrimin tinactin antifungal ointment afrin nasal decongestant chlortrimeton antihistamine claritin allergy coricidin drixoral cold decongestant product correctol laxative bain soleil coppertone solarcaine sun care product recent development response decline sale earning company initiate number action include new management team appoint implement change describe follow section quarterly dividend reduce cent cent common share program entitle value enhancement initiative vei commence vei tool design enable company save spend wisely key costcutte initiative implement include eliminate employee bonus company standard plan table content eliminate payout company profit sharing plan eliminate routine merit increase exception local contract practice prevent action customer contact employee employee dedicated fulfillment company fda consent decree obligation businesscritical employee target overall reduction payroll relate expense percent exclude payroll expense associate customer contact employee employee dedicated fulfilling company fda consent decree obligation step achieve target voluntary early retirement program verp united states approximately employee elect retire program instal global procurement program exercise tight control new hire cut travel cost reduce meeting expense table content net sale major product therapeutic category dollar million year end december percent change antiinfective anticancer caelyx intron franchise remicade temodar antiinfective anticancer allergy respiratory clarinex claritin nasonex proventil allergy respiratory cardiovascular integrilin cardiovascular dermatological pharmaceutical worldwide pharmaceutical otc otc claritin otc foot care sun care animal health consolidate net sale meaningful intron franchise consist intron pegintron rebetol sales clarinex launch international market include claritin sale table content company reportable segment prescription pharmaceutical consumer health care animal health segment sale profit datum follow consistent company current management reporting structure establish second quarter prior period information present restate comparable basis prescription pharmaceutical segment discover develop manufacture market human ethical pharmaceutical product consumer health care segment develop manufacture market otc foot care sun care product animal health segment discover develop manufacture market animal health product net sale segment dollar millions year end december prescription pharmaceutical consumer health care animal health consolidate net sale profit segment dollar millions year end december prescription pharmaceutical consumer health care animal health corporate consolidated lossprofit tax corporate include charge million relate voluntary early retirement program special charge footnote item financial statement supplementary datum additional information estimate charge relate reportable segment follow prescription pharmaceutical million consumer health care million animal health million corporate million corporate include provision increase litigation reserve asset impairment charge interest income expense foreign exchange gain loss headquarters expense miscellaneous item accounting policy segment report describe summary significant accounting policy table content company subsidiary country outside united states sale outside united states comprise percent million consolidated net sale percent million percent million single foreign country france japan italy account percent consolidated net sale past year france account percent million percent million percent million consolidated net sale respectively japan account percent million percent million percent million consolidated net sale respectively italy account percent million percent million percent million consolidated net sale respectively net sale geographic area dollar millions united states europe canada latin america pacific area asia consolidate net sale net sale present geographic area company customer locate percent million percent million percent million respectively consolidated net sale mckesson corporation major pharmaceutical health care product distributor percent million percent million percent million respectively consolidated net sale amerisourcebergen corporation major pharmaceutical health care product distributor longlive asset geographic location dollar millions united states ireland singapore puerto rico total longlive asset show geographic location primarily property table content sale product comprise percent company international sale year end december follow dollar million international intron franchise clarinex otc claritin remicade company disaggregate asset segment basis internal management report information present prescription drug introduce known physician pharmacist hospitals manage care organization buy group train professional sale representative sell hospital certain manage care organization wholesale distributor retail pharmacist prescription product introduce known journal advertise direct mail advertising distribute sample physicians television radio internet print advertising medium animal health product promote veterinarian distributor animal producer foot care otc sun care product sell wholesale retail drug food chain mass merchandiser outlet promote directly consumer television radio internet print advertising media pharmaceutical industry highly competitive include large company substantial resource research product development advertising promotion field sell support numerous domestic international competitor industry principal competitive technique company product include research development new improved product high product quality varied dosage form strength switch prescription product nonprescription status united states company product subject increasingly competitive pricing manage care group institution federal state government entity agency buy group seek price discount rebate governmental pressure dispense generic product significantly reduce sale certain product long protect patent datum exclusivity arrangement fda company subsidiary license right number patent patent application united states abroad patent patent application relate company significant product include limitation clarinex claritin family product intron peg intron rebetol nasonex zetia material importance company compound patent loratadine expire june table content market exclusivity claritin expire december patent cover compound desloratadine formulation thereof method treatment desloratadine relate claritin set expire april month market exclusivity attach end desloratadine patent relate claritin expire october sixmonth period exclusivity grant company conduct pediatric clinical trial request fda addition generic form ribavirin expect enter market assume fdas approval generic ribavirin patent subject litigation describe item legal proceeding worldwide company product sell trademark trademark consider aggregate material importance business protect registration common law united states market product sell raw material essential company available adequate quantity number potential supplier energy expect available company sufficient quantity meet operating requirement seasonal pattern pronounce effect consolidated operation company foreign operation foreign activity carry primarily whollyowne subsidiary market potential adequate circumstance permit addition company represent market licensee distribution arrangement approximately employee outside united states foreign operation subject certain risk inherent conduct business overseas risk include possible nationalization expropriation importation limitation pricing restriction restrictive governmental action economic destabilization fluctuation foreign currency exchange rate impact company consolidate financial result additional information foreign operation item management discussion analysis operation financial condition segment information describe research development company research activity primarily aim discover develop new enhance prescription product medical commercial significance company sponsor research development expenditure million million million respectively research expenditure represent approximately percent consolidated net sale percent consolidate net sale approximately percent consolidated net sale addition company share research development cost relate cholesterol joint venture merck table content million include equity income cholesterol joint venture statement consolidated operation company research activity concentrate therapeutic area allergic inflammatory disorder infectious disease oncology cardiovascular disease central nervous system disorder company substantial effort direct biotechnology gene therapy immunology research activity include expenditure internal research effort research collaboration partner pharmaceutical compound vary stage development predict compound available commercial sale government regulation pharmaceutical company subject extensive regulation number national state local agency particular importance fda jurisdiction company business administer requirement cover testing approval safety effectiveness manufacturing labeling marketing company product fda regulate conversion pharmaceutical prescription otc status extent fda requirement andor review affect resource necessary develop new product bring market united states ongoing basis fda regulate facility procedure manufacture pharmaceutical product united states sale united states product facility manufacture accordance good manufacturing practice gmp establish fda fda periodically inspect company facility procedure evaluate compliance company announce reach agreement fda consent decree resolve issue involve company compliance current good manufacturing practice cgmp certain manufacturing facility new jersey puerto rico district court district new jersey approve enter consent decree term consent decree company agree pay total million government equal installment million installment pay second installment pay previously report company accrue million provision consent decree fourth quarter consent decree require company complete number action event certain action agree consent decree satisfactorily complete time fda assess payment deadline miss consent decree require company develop submit fdas concurrence comprehensive cgmp work plan company manufacture facility new jersey puerto rico cover decree company receive fda concurrence propose cgmp work plan table content cgmp work plan contain number significant step timely satisfactory completion subject payment thousand business day deadline miss payment exceed million million year payment subject overall cap million connection discussion fda company cgmp work plan pursuant term decree company fda enter letter agreement date april letter agreement company fda agree extend month time period company incur payment describe respect certain significant step propose date december letter agreement increase yearly overall cap payment describe addition decree require company complete program revalidation finish drug product bulk active pharmaceutical ingredient manufacture covered manufacturing facility company require consent decree complete revalidation program bulk active pharmaceutical ingredient september finish drug december general timely satisfactory completion revalidation subject payment thousand business day deadline miss subject cap describe product schedule revalidation certify validate date validation schedule fda assess payment percent net domestic sale uncertified product validation certify general product schedule revalidation consent decree certify month schedule date company cease production product certification obtain completion significant step work plan completion revalidation program subject thirdparty expert certification accept fda consent decree provide company believe able meet deadline company right show good cause request extension deadline connection cgmp work plan revalidation program guarantee fda grant request company believe significant progress meet obligation consent decree possible company fail complete significant step revalidation prescribe deadline party expert certify completion significant step revalidation fda disagree expert certification significant step revalidation case possible fda assess payment describe company expense payment assess decree incur failure comply governmental regulation result delay release product delay approval new product seizure recall product suspension revocation authority necessary production sale product fine civil criminal sanction table content company activity outside united states subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing company product regulatory requirement vary country country fda approval approval european medicine evaluation agency obtain product approval product comparable regulatory authority country outside united states european union case obtain prior marketing product country approval process rigorous country country time require approval long shorter require united states approval country assure product approve country international market company operate environment governmentmandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug enact acrosstheboard price cut method cost control recent year legislative proposal offer congress state legislature effect major change affect health care system change material company addition outpatient prescription drug benefit medicare states pass legislation federal state legislative administrative proposal possible include price patient reimbursement constraint medicine mandate discount supplemental rebate expansion exist governmental program new patient population restriction access certain product similar issue arise country outside united states possible predict outcome initiative effect operation cash flow reasonably estimate company predict net effect medicare prescription drug benefit market sale program effect company lead drug cover medicare temodar integrilin intron relatively small portion sale medicare population clarinex hepatitis franchise company experience expand utilization zetia new drug company pipeline great consequence company legislation impact pricing rebate discount company subject jurisdiction federal state regulatory enforcement department agency federal trade commission ftc department justice department health human services united states company subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy table content environment date compliance federal state local environmental protection law materially adverse effect company company continue necessary expenditure environmental protection worldwide capital expenditure include approximately million environmental control purpose anticipate continued compliance environmental regulation significantly affect company financial statement competitive position additional information environmental matter item legal proceeding employee approximately people employ company december available information company make annual report quarterly report form current report form amendment report file sec available free charge web site soon reasonably practicable material electronically file sec company address world wide web scheringploughcom company begin practice quarter report available company web site hour filing report file company sec read copy secs public reference room fifth street washington information operation public reference room obtain call sec sec sec maintain internet site wwwsecgov contain report proxy information statement information issuer file electronically sec item property companys corporate headquarter locate kenilworth new jersey principal manufacturing facility locate kenilworth new jersey miami florida omaha nebraska cleveland tennessee puerto rico argentina belgium canada france germany ireland italy japan mexico singapore spain company principal research facility locate kenilworth union new jersey palo alto san diego california elkhorn nebraska company announce reach agreement fda enter consent decree resolve issue involve company compliance cgmp certain manufacturing facility new jersey puerto rico refer government regulation section item form additional information consent decree table content property own company property generally maintain insure generally good operating condition company manufacture facility capacity consider appropriate meet company need table content item legal proceeding background company responsibilitie environmental cleanup state local federal law include comprehensive environmental response compensation liability act commonly know superfund superfund site equivalent site state law company allege potentially responsible party prp company estimate obligation cleanup cost superfund site base information obtain federal environmental protection agency epa equivalent state agency andor study prepare independent engineer probable cost pay prps company record liability environmental assessment andor cleanup probable loss incur reasonably estimate company involve claim legal proceeding nature consider normal business include product liability case company adjust accrue liability reflect current good estimate probable loss exposure good estimate determinable company accrue minimum probable range liability record liability matter december relate expense incur month end december material expect insurance recovery consider determine cost environmentalrelate liability management believe matter discuss remainder section remote time material liability excess amount accrue incur respect matter discuss remainder section note practicable estimate range reasonably possible loss reserve include financial statement resolution matter discuss remainder section individually aggregate material adverse effect company result operation financial condition management review status matter discuss remainder section ongoing basis time time settle resolve term condition management believe good interest company company aware settlement matter type set forth remainder section particular investigation frequently involve fine andor penalty material financial condition result operation entity enter settlement assurance company prevail matter settlement reach acceptable term include scope release provide amount exceed amount reserve acceptable settlement reach assurance investigation litigation commence raise similar type issue potentially expose company additional material liability company predict timing resolution matter outcome table content environmental resident vicinity publicly own wastewater treatment plant barceloneta puerto rico file lawsuit plant owner operator numerous company discharge plant include subsidiary company damage injunctive relief relate odor allegedly come plant connect sewer lawsuit class action claim damage million trial date set case matter submit mediation november receive general notice potential liability epa address arnoscholl adhesive tape inc subsidiary company relate lake culmet cluster site chicago illinois potentially responsible party site scheringplough respond information request new jersey department environmental protection relate contamination low passaic river basin scheringplough deny connection contamination late september department direct prps contaminate site assess restore natural resource damage low passaic river basin department scheringplough prp department send scheringplough letter receive september state company legally responsible damage natural resource state department adopt regulation cover liability calculate making difficult accurately predict ultimate extent company exposure patent matter claritin patent february geneva pharmaceuticals inc geneva submit abbreviate new drug application anda fda seek market generic claritin tablet expiration company desloratadine compound patent company believe protect claritin geneva allege desloratadine compound patent invalid patent material company business march company file suit federal court seek rule genevas anda submission constitute infringement company desloratadine compound patent challenge patent merit addition geneva follow company similar anda submission generic claritin tablet zenith goldline pharmaceutical mylan pharmaceuticals inc teva pharmaceuticals usa inc teva ranbaxy pharmaceuticals inc ranbaxy genpharm incorporate perrigo company perrigo follow company similar anda submission generic claritin syrup teva copley pharmaceuticals inc novex pharma alpharma uspd inc taro pharmaceuticals usa inc morton grove pharmaceuticals inc perrigo andrx pharmaceuticals llc andrx impax laboratories inc impax similar anda submission generic claritind hour claritind hour formulation ranbaxy similar anda submission generic claritind hour formulation esi lederle inc lederle subsidiary wyeth similar anda submission generic claritin reditab formulation follow company submit paper new drug application paper nda section federal food drug cosmetic act seek market generic otc form claritin prior expiration company desloratadine compound patent whitehall table content robins healthcare division wyeth otc reditab formulation mcneil consumer healthcare mcneil otc tablet perrigo otc tablet case company file suit federal court seek rule applicable anda paper nda submission propose marketing generic prescription otc product constitute infringement company desloratadine compound patent challenge patent merit august federal district court new jersey rule motion summary judgment find certain claim desloratadine compound patent anticipate prior patent valid august district court decision sustain appellate court october appellate court deny company petition rehear ruling action defendant infringement desloratadine compound patent manufacturer loratadine proceed company assert impaxs andrxs andas generic claritind hour formulation infringe company patent cover claritind hour formulation october company settle litigation impax andrx license patent rebetol patent august geneva pharmaceuticals technology corp geneva pharmaceuticals river pharmaceutical llc river january teva submit separate anda fda seek market generic form rebetol ribavirin capsules united states expiration company patent cover ribavirin formulation geneva pharmaceutical river teva assert infringe company rebetol patent andor patent invalid rebetol patent material company business september october march company file suit federal court seek ruling anda submission geneva pharmaceutical river teva respectively constitute infringement company patent challenge company patent merit company enter separate licensing agreement river geneva pharmaceuticals teva settle patent litigation company river teva geneva pharmaceuticals grant river geneva pharmaceuticals teva nonexclusive nonsublicensable license company ribavirin patent agreement subject dismissal river geneva pharmaceuticals tevas report patent litigation ribapharm inc subsidiary valeant pharmaceutical international ribapharm litigation dismiss defendant motion summary judgment july ribapharm appeal summary judgment decision ribapharm petitioned fda deny approval river geneva pharmaceuticals teva products fda act ribapharm petition date report prime pac prrs patent january jury find company prime pac prrs porcine respiratory reproductive syndrome vaccine infringe patent own boehringer ingelheim vetmedica inc injunction issue august bar sale company vaccine company posttrial motion reversal jurys verdict new trial deny september company appeal verdict affirm appellate court february litigation damages phase case ongoing trial determine damage schedule table content investigation pennsylvania investigation october company receive subpoena attorney office eastern district pennsylvania pursuant health insurance portability accountability act concern company contract pharmacy benefit manager pbms manage care organization provide disease management service connection marketing pharmaceutical product appear subpoena number address industry participant inquiry thing pharmaceutical marketing practice government inquiry focus thing company disease management marketing program arrangement comply federal health care law value disease management program marketing program arrangement include calculation rebate government company cooperate investigation march attorney office begin issue grand jury subpoena grand jury investigation appear focus transaction manage care organization government believe company offer provide deeply discount pharmaceutical product know nominally price product generally exclude medicaid rebate calculations free discount disease management service marketing program arrangement deliver value order place retain company major pharmaceutical product manage care organization formulary grand jury appear investigate thing transaction describe conduct relate thereto violate federal antikickback statute value item service describe include company calculation medicaid rebate outcome investigation include commencement civil andor criminal proceeding involve substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program company predict investigation affect marketing practice sale quarter company increase litigation reserve relate investigation investigation describe attorney office district massachusetts million increase reserve reflect mature discussion office particularly eastern district pennsylvania adjustment company estimate minimum liability relate investigation compliance generally accept accounting principle gaap gaap company require estimate recognize minimum liability loss probable well estimate loss fourth quarter company increase litigation reserve million matter company predict timing resolution matter company note total reserve reflect estimate final settlement adjudication matter possibly materially exceed aggregate liability accrue company materially adverse effect operation financial condition company awp investigation company respond investigation department health human services department justice committee energy commerce house representatives certain state certain industry company practice average wholesale price awp investigation include department justice table content review merit federal action file private entity behalf united states district court southern district florida investigation attorney office district massachusett inter alia awp set pharmaceutical company certain drug improperly exceed average price pay dispenser consequence result unlawful inflation certain government drug reimbursement base awp march company receive subpoena massachusetts attorney general office seek document concern use awp pricing andor marketing practice company cooperate investigation outcome investigation include imposition substantial fine penalty injunctive administrative remedy massachusetts investigation attorney office district massachusetts investigate company sale product manufacture private label arrangement manage care organization include company medicaid good price calculation early november company serve additional grand jury subpoena attorney district massachusetts information subpoena seek broad range information concern company sale marketing clinical trial practice program respect intron rebetron temodar company sale marketing contact manage care organization doctor company offer provision grant honorarium item service value manage care organization physician group doctor educational institution company understand investigation focus certain sale marketing clinical trial practice conduct relate thereto certain instance relate use abovementione product indication fda approval obtain socalle offlabel use violation federal law regulation respect offlabel promotional activity investigation appear focus drug sample clinical trial grant item service value give provider incentivize prescribe abovementione product include offlabel use violation federal health care antikickback law company implement certain change sale marketing clinical trial practice continue review practice ensure compliance relevant law regulation company cooperate investigation future sale intron rebetron temodar adversely affect company time predict ultimate impact sale outcome investigation include commencement civil andor criminal proceeding involve imposition substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program quarter company increase litigation reserve relate investigation attorney office district massachusetts describe paragraph paragraph immediately precede investigation describe attorney office eastern district pennsylvania million increase litigation reserve reflect adjustment company estimate minimum liability relate investigation compliance gaap gaap company require estimate recognize minimum liability loss probable well estimate loss fourth quarter company increase litigation reserve million matter company note total reserve reflect estimate final settlement table content adjudication matter possibly materially exceed aggregate liability accrue company materially adverse effect operation financial condition company company predict timing resolution matter outcome report file scheringplough disclose connection abovedescribe investigation attorney office district massachusetts sale marketing clinical trial practice matter schere corporation wholly own significant operating subsidiary scheringplough receive letter boston target letter office advise schering corporation include subsidiary division target federal criminal investigation respect area provide remuneration drug sample clinical trial grant item service value manage care organization physician induce purchase schering pharmaceutical product payment federal health care program sale misbrande unapproved drug company understand mean drug promote indication approval fda obtain socalle offlabel use submit false pharmaceutical pricing information government purpose calculate rebate require pay medicaid program fail include price product repackage arrangement manage care customer price free nominally price good provide customer induce purchase schering product document destruction obstruction justice relate government investigation target define department justice guideline person prosecutor grand jury substantial evidence link commission crime judgment prosecutor putative defendant attorney manual section consumer product matter department justice antitrust division investigate company consumer product division enter agreement company low commission rate consumer product broker february antitrust division serve grand jury subpoena company seek document time company cooperate investigation nitrodur investigation august company receive civil investigative subpoena issue office inspector general department health human service seek document concern company classification nitrodur medicaid rebate purpose company use nominal pricing bundle product table content sale company cooperate investigation appear subpoena number address pharmaceutical company concern inquiry issue relate payment government rebate security class action litigation february company state press release fda conduct inspection company manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current good manufacturing practice primarily relate production process control procedure day february lawsuit file district court district new jersey company certain name officer allege violation section securities exchange act rule promulgate thereunder additional lawsuit tenor follow complaint consolidate action district court district new jersey lead plaintiff florida state board administration appoint court july october consolidated amend complaint file allege violation describe second sentence paragraph purport represent class shareholder purchase share company stock february companys motion dismiss consolidated amend complaint deny october court certify shareholder class discovery ongoing addition lawsuit describe immediately precede paragraph lawsuit file district court district new jersey lawsuit file new jersey state court company nominal defendant certain officer director director seek damage behalf company include disgorgement trading profit defendant allegedly obtain basis material nonpublic information complaint lawsuit relate issue describe company february press release allege failure disclose material information breach fiduciary duty director federal court lawsuit include allegation relate investigation attorney office eastern district pennsylvania district massachusetts ftcs administrative proceeding company lawsuit state texas warrick pharmaceuticals warrick companys generics subsidiary describe lawsuit shareholder derivative action purport assert claim behalf company demand board director decision company pursue claim august plaintiffs new jersey state court shareholder derivative action move dismiss voluntarily complaint action motion grant shareholder derivative action pende district court district new jersey consolidate action early stage january company receive demand letter date december law firm involve derivative action describe behalf shareholder involve derivative action demand board director bring claim behalf company base allegation substantially similar allege derivative action january board director adopt board resolution establish evaluation committee consist table content director investigate review analyze fact circumstance surround allegation demand letter consolidate amend derivative action complaint describe reserve board authority discretion exercise business judgment respect proper disposition demand committee engage independent outside counsel advise issue report finding investigation independent director board late october report determine shareholder demand refuse find liability officer director november board adopt recommendation evaluation committee august prescription access litigation project pal bostonbased group form litigate drug company issue press release state pal member file lawsuit new jersey state court company december company serve amend complaint case suit pal purport class action allege thing company directtoconsumer advertising falsely depict benefit claritin violation new jersey consumer fraud act february company file motion dismiss case court dismiss complaint entirety failure state claim plaintiff appeal deny new jersey state court plaintiff request new jersey supreme court hear case request deny end litigation company defendant number purport nationwide state class action lawsuit plaintiff seek refund purchase price laxative phenylpropanolaminecontaine coughcold remedy ppa product purchase pharmaceutical manufacturer codefendant lawsuit general plaintiff claim purchase pay product know certain defect medical risk attendant use litigation claim relate company ppa product court national class action suit state class action suit deny certification dismiss suit similar application dismiss new jersey remain statewide class action suit involve company pende approximately individual lawsuit relate laxative product ppa product recall albuterolvancerilvancenase inhaler pende company seek recovery personal injury death number lawsuit punitive damage claim march company serve putative class action complaint file district court new jersey allege company richard jay kogan resign chairman board november retire chief executive officer president director company april companys employee saving plan plan administrator breach fiduciary obligation certain participant plan allegation primarily relate disclosure companys good manufacturing practice issue discuss early security class action litigation section relation company disclosure consent decree fda relate matter disclosure meeting investor week september communication discuss sec inquiry relate litigation table content company serve second putative class action complaint file court allegation nearly identical complaint file march october consolidated amend complaint file name additional defendant follow director eugene mcgrath donald miller carl mundy patricia russo kathryn turner director james wood regina herzlinger corporate officer consolidate amend complaint contain allegation associate boston target letter describe investigation section footnote company file motion dismiss complaint august lawsuit file new jersey superior court chancery division union county serve company nominal defendant company outside director allege breach fiduciary duty director relate company receipt boston target letter describe investigation section footnote action temporarily stay pende adjudication separate relate action frame shareholder request access company book record seek document information relate massachusetts investigation antitrust ftc matter company defendant numerous antitrust action commence start state federal court independent retail pharmacy chain retail pharmacy consumer plaintiff allege price discrimination andor conspiracy company defendant restrain trade jointly refuse sell prescription drug discount price plaintiff company february agree settle federal class action behalf approximately twothird retail pharmacy united states total million pay district court illinois approve settlement federal class action seventh circuit court appeal dismiss appeal settlement subject review april certain plaintiff federal class action commence purport class action district court illinois company defendant settle previous federal class action complaint allege defendant conspire implement settlement commitment follow settlement discuss district court deny plaintiff motion preliminary injunction hear company settle dismiss motion state court retailer consumer action settlement amount material company federal court illinois remand conspiracy portion case retailer opt class action district court file case consolidate federal district court brooklyn new york federal court illinois jurisdiction robinson patman portion case trial conspiracy claim set begin october plaintiffs antitrust action generally seek treble damage unspecified injunction allegedly unlawful conduct table content april ftc start administrative proceeding company upshersmith inc upshersmith lederle complaint allege anti competitive effect settlement patent lawsuit company lederle company upshersmith lawsuit settle related generic version kdur company longacte potassium chloride product subject andas file lederle upshersmith june administrative law judge oversee case issue decision patent litigation settlement comply law respect dismiss claim company appeal decision commission file ftc staff december commission issue opinion reverse decision administrative law judge find violation antitrust law rule instead company settlement fact violate law ftcs decision involve monetary penalty company appeal decision federal court appeal kdur potassium chloride supplement cardiac patient follow commencement ftc administrative proceeding allege class action suit file behalf direct indirect purchaser kdur company upshersmith lederle federal state court suit allege essentially fact claim violation federal state antitrust law state statutory andor common law cause action motion dismiss action pende pricing matter quarter warrick pharmaceuticals warrick companys generics subsidiary sue state texas june company subsidiary schering corporation add defendant lawsuit allege warrick supply state false report wholesale price cause state pay medicaid claim prescription warrick albuterol sulfate solution inhaler higherthanjustifie level state seek damage approximately million warrick include treble damage penalty trial date april set outcome litigation result imposition fine penalty injunctive remedy case go trial assurance damage seek state exceed set forth state petition december pal file class action suit federal court massachusetts company september consolidated complaint file court result coordination multidistrict litigation panel federal court awp case country consolidate complaint allege company warrick conspire provider defraud consumer report fraudulently high awps prescription medication reimburse medicare thirdparty payer complaint seek declaratory judgment unspecified damage include treble damage include pal litigation describe prior paragraph lawsuit allege company warrick report inflated awps prescription pharmaceutical cause state federal entity thirdparty payer excess reimbursement provider action allege company warrick fail report accurate price medicaid rebate program underpaid rebate state action begin october bring state attorney general table content private plaintiff nonprofit organization employee benefit fund allege violation federal state law include fraud antitrust racketeer influence corrupt organization act rico claim addition warrick company defendant number lawsuit state court action generally bring states andor political subdivision seek unspecified damage include treble punitive damage sec inquiry relate litigation sec investigate compliance polish subsidiary certain pharmaceutical company foreign corrupt practice act pursuant order date november company voluntarily produce document relate polish subsidiary subsidiary country company continue cooperate sec request company cooperate inquiry police katowice poland ask related information september sec company announce settlement sec enforcement proceeding company richard jay kogan chairman chief executive officer meeting hold investor week september communication admit deny allegation company agree commit future violation regulation relate security law pay civil penalty million kogan pay civil penalty thousand federal putative class action file company kogan meeting hold investor week september communication consolidate pursuant consolidation amend complaint date march file allege violation section securities exchange act relate alleged disclosure meeting mention paragraph company file motion dismiss class action plaintiff seek leave court file second amend complaint october company move dismiss second amend complaint september lawsuit file new jersey superior court union county richard jay kogan company outside director allege breach fiduciary duty fraud deceit negligent misrepresentation relate alleged disclosure meeting mention company remove case federal court motion remand state court pende matter company subject pharmacovigilance reporting requirement country jurisdiction include united states european union member states requirement differ jurisdiction jurisdiction include requirement report adverse event occur patient particular drug order alert manufacturer drug governmental agency potential problem pharmacovigilance inspection official british french medicine agency conduct request european agency evaluation medicinal product emea deficiency report process identify company take table content urgent action rectify deficiency quickly possible company know action emea national authority response finding possible action include inspection demand improvement report system criminal sanction company andor responsible individual change condition marketing authorization company product april company receive notice false claim act complaint bring individual purport act behalf government approximately pharmaceutical company district court northern district texas complaint allege pharmaceutical company include company defraud united states sale federal governmental agency drug allegedly manufacture manner comply current good manufacturing practice company defendant file motion dismiss action july tax matter october irs auditor assert report company liable additional tax tax year report allege interest rate swap company enter unrelated party recharacterize loan affiliate company result additional tax income tax seek irs auditor relate recharacterization approximately million plus interest depend court company choose litigate case require pay tax possibly interest prior litigation company estimate interest approximately million company prevail litigation amount pay prior litigation return company plus accrued interest company choose litigate case court require payment tax interest prior litigation management believe probable matter litigate management believe tax reserve sufficient absorb loss result unfavorable outcome litigation item submission matter vote security holder applicable table content executive officer registrant follow information executive officer include accordance iii item corporate officer list officer elect serve year successor shall duly elect current position business experience age robert bertolini present position executive vice president chief partner pricewaterhousecooper financial officer ron cheeley present position senior vice president group vice president global compensation global human resource benefit pharmacia corporation joseph connor present position executive vice president general counsel carrie cox present position executive vice president president executive vice president president global global pharmaceutical prescription business pharmacia corporation senior vice president head global business management pharmacia upjohn douglas gingerella present position vice president corporate staff vice president corporate audits audits fred hassan present position chairman chief executive officer chairman board chief executive officer president pharmacia corporation chief executive officer pharmacia corporation chief executive officer pharmacia upjohn table content current position business experience age thomas kelly present position vice president controller joseph larosa present position staff vice president secretary staff vice president commercial law associate general counsel senior legal director legal director kevin moore present position vice president treasurer daniel nichols present position senior vice president tax cecil pickett phd present position vice president president schering executive vice president discovery research plough research institute scheringplough research institute brent saunder present position senior vice president global partner pricewaterhousecooper chief compliance business practice risk officer coventry health care officer define rule securities exchange act table content item market registrant common equity relate stockholder matter common share dividend share price datum approximate number holder record set forth item financial statement supplementary datum item select financial datum dollar million share figure operate result net sale lossincome income taxis net lossincome dilute lossearning common share basic lossearning common share investment research development capital expenditure financial condition property net total asset longterm debt shareholder equity net book value common share financial statistic net lossincome percent sale return average shareholder equity effective tax rate datum cash dividend common share cash dividend common share depreciation amortization number employee average share outstanding diluted earning common share million average share outstanding basic earning common share million common share outstanding yearend million table content include special charge respectively special charge footnote item financial statement supplementary datum additional information effective tax rate percent exclude nontax deductible provision increase litigation reserve table content item management discussion analysis financial condition result operation executive summary company scheringplough worldwide pharmaceutical company commit discover develop manufacturing marketing new therapy treatment enhance human health company primary business strategy continually discover license human pharmaceutical product patent protect extended period time product patent expire generic competition occur result substantial decline product average selling price scheringplough lead consumer product brand overthecounter otc foot care sun care markets global animal health business government regulatory agency world regulate company discovery development manufacturing marketing effort food drug administration united states fda pivotal regulator company business united states pricing company pharmaceutical product subject competitive pressure manage care organization seek price discount united states company require provide statutorily define rebate government agency order participate medicaid veterans health care program governmentfunde program international market company operate environment government mandate costcontainment program company ship pharmaceutical product wholesaler distributor market product health care professional manage care organization less extent patient key performance indicator kpi company percentage market share product market share company major product discuss section follow current state company past year company experience confluence negative event summarize follow company work fda resolve issue involve company compliance current good manufacturing practice cgmp certain manufacturing site new jersey puerto rico company reach formal agreement fda consent decree term consent decree company agree payment total million revalidate manufacturing process site manufacture site remained open period consent table content decree place significant additional control production release product site include review thirdparty certification production variance product review thirdparty certification batch production record thirdparty certification cgmp improvement project result high cost reduce output facility addition company find necessary discontinue certain old product impact consent decree discuss detail section follow certain company sale marketing practice investigation attorney office pennsylvania massachusetts investigation pose significant risk company cause company significantly increase litigation reserve matter discuss detail section follow december company switch formulation claritin united states prescription otc status switch follow loss marketing exclusivity product average unit sell price otc product low price prescription market loss marketing exclusivity company face additional competition comparable brand generic otc marketplace claritin united states company lead product term sale term profit result company experience rapid sharp material decline earning cash flow begin company expect earning recover loss sale claritin time company introduce new product recovery year company lead franchise combination pegylate interferon pegintron ribavirin rebetol treat hepatitis late competitor enter hepatitis marketplace version pegylate interferon ribavirin prior introduction compete product company hold lead position hepatitis market introduction competitor company market share fall significantly decline sale exacerbate overall earning cash flow decline addition generic form rebetol approve time important market occur company market share sale decline table content matter result follow cash flow decline significantly particularly united states majority research conduct dividend pay payment arise investigation conduct attorney office reduce cash flow united states addition company credit rating reduce impact low credit rating company overall liquidity discuss detail section follow company manufacturing site operate optimum level sale decline reduction output relate consent decree time overall cost operating manufacturing site increase consent decree activity impact fact reduction profit margin time major investment manufacturing capacity impair company continue review carry value asset indication impairment future event decision lead asset impairment loss accelerate depreciation shorten asset live response company initiate follow action new management team appoint implement change describe follow section quarterly dividend reduce cent cent common share program entitle value enhancement initiative vei commence vei tool design enable company save spend wisely key costcutte initiative implement include eliminate employee bonus company standard plan eliminate payout company profit sharing plan eliminate routine merit increase exception local contract practice prevent action customer contact employee employee dedicated fulfillment company fda consent decree obligation businesscritical employee target overall reduction payroll relate expense percent exclude payroll expense associate customer contact employee employee dedicated fulfilling company fda consent decree obligation step achieve target voluntary early retirement program verp united states approximately employee elect retire program instal global procurement program exercise tight control new hire cut travel cost reduce meeting expense table content positive company enter cholesterolreduction market launch zetia ezetimibe marketing application ezetimibesimvastatin combination submit file september cholesterolreduction market single large pharmaceutical market world management believe product potential enable company loss claritin build long term financial strength addition company believe potentially valuable pharmaceutical compound early stage research pipeline company aggressively pursue licensing opportunity researchbase pharmaceutical company outlook yearoveryear comparison negatively impact number factor include follow company experience downward slope sale market share key profitgenerating product company make significant investment sale marketing support aim stabilize market share key profitgenerating product company expect generic competition rebetol market begin contraction worldwide hepatitis market begin continue absence losec revenues europe end agreement astrazeneca quarter losec revenue million ability company rebuild financial strength highly dependent success cholesterol joint venture merck inc merck joint venture highly successful company able rebuild financial strength turn operating performance begin joint venture highly successful company rely success earlystage pipeline drug license opportunity significant change corporate strategy combination reader note significant uncertainty inherent factor enable company rebuild financial strength net sale consolidate net sale total billion decrease billion percent compare period consolidate net sale reflect volume decline percent favorable foreign exchange rate impact percent unfavorable price impact percent net sale united states decrease percent versus net sale internationally advanced percent international sale include favorable foreign exchange rate impact percent table content consolidate net sale billion increase million percent versus reflect price increase impact percent favorable foreign exchange rate impact percent sale volume unchanged versus net sale major therapeutic category year end december follow dollar million increase decrease antiinfective anticancer allergy respiratory cardiovascular dermatological pharmaceutical global pharmaceutical otc foot care sun care consumer health care animal health consolidate net sale meaningful percentage certain prior year amount reclassify conform current year presentation net sale global antiinfective anticancer product decrease percent compare sale intron franchise primarily treatment hepatitis decrease percent billion market share decline change trade inventory level low sale japan market share intron franchise decline reflect entrance competitor new product hepatitis market previously report company anticipate potential generic competition united states rebetol sale rebetol million intron franchise include anticancerantiviral agent intron injection monotherapy combination rebetol capsule treat hepatitis peg intron powder injection longeracte form intron monotherapy combination rebetol treat hepatitis net sale antiinfective anticancer therapeutic category benefit international sale remicade treatment rheumatoid arthritis crohns disease ankylose spondylitis net sale remicade million percent million primarily europe increase patient utilization global sale temodar capsule treat certain type brain tumor increase percent million increase market penetration international sale caelyx longcirculating pegylate liposomal formulation doxorubicin hydrochloride increase percent million increase table content patient utilization couple ongoing launch new indication treatment metastatic breast cancer patient increase cardiac risk net sale global antiinfective anticancer product rise percent compare lead october market introduction pegintron combination rebetol hepatitis united states continue rollout combination therapy european market december launch rebetol combination intron japan sales antiinfective anticancer category benefit high international sale remicade global sale temodar reflect increase market penetration global net sale allergy respiratory product decrease percent percent category sale negatively impact rapid decline sale prescription claritin result loss market exclusivity united states conversion prescription otc status december global sale prescription claritin million compare billion billion sale prescription claritin recognize million versus sale billion billion global net sale clarinex treatment seasonal outdoor allergy yearround indoor allergy million increase percent reflect continued conversion patient prescription claritin clarinex couple launch clarinex international market factor temper contraction prescription antihistamine market follow launch otc claritin change trade inventory level clarinex continue experience intense competition allergy market global sale clarinex million clarinex launch united states january net sale nasonex nasal spray oncedaily corticosteroid nasal spray allergy decrease percent million change trade inventory level market share decline united states nasonex experience intense competition allergy market international sale nasonex grow percent million market share gain net sale nasonex essentially flat versus market share decline united states temper market share gain international market global net sale cardiovascular product increase percent sale integrilin injection glycoprotein platelet aggregation inhibitor treatment patient acute coronary syndrome increase percent million increase patient utilization united states temper decline trade inventory level global net sale cardiovascular product decrease percent low sale kdur sustainedrelease potassium chloride supplement subject generic competition partially offset decline high sale integrilin increase patient utilization increase market penetration net sale consumer health care product include otc foot care sun care product increase million percent increase million otc product net sale increase million million launch otc table content claritin december sale otc claritin million million quarter company begin face additional privatelabel competition otc claritin initial day period exclusivity expire otc generic competitor comparison versus negatively impact manufacturing issue otc product net sale foot care product decrease million percent nonrecurrence launch lotrimin ultra topical antifungal foot care sale decrease percent increase competition temper launch lotrimin ultra net sale sun care product decrease million percent primarily unfavorable weather condition united states sun care sale decrease percent low sale bain soleil product global net sale animal health product increase percent million sale favorably impact foreign exchange percent offset continued manufacture supply issue describe additional factor influence operation global net sale animal health product decrease percent challenge global market condition couple manufacturing issue table content summary cost expense equity income dollar million increase decrease cost sale net sale sell general administrative net sale research development net sale income expense net net sale special charge net sale equity income cholesterol joint venture net sale meaningful percentage certain prior year amount reclassify conform current year presentation cost sale percentage net sale increase primarily change product sale mix result loss sale prescription claritin increase result high unit manufacturing cost include effect low production volume couple increased spending company cgmp compliance effort cost sale percentage net sale increase primarily shift sale product royalty pay high cost associate manufacturing issue sell general administrative expense decrease percent billion versus billion decrease low marketing expense global pharmaceutical business include zero payout profit sharing routine bonus addition field force incentive decline decrease temper high promotion otc claritin foreign exchange ratio net sale percent high ratio percent primarily lower overall sale report sell general administrative expense increase percent ratio net sale increase percent percent increase spending support continue rollout new recently introduce product international market research development spending increase percent billion represent percent net sale research development expense increase percent table content billion represent percent net sale change spend year reflect timing company fund internal research effort research collaboration partner discover develop steady flow innovative product change reflect presentation research development cost relate cholesterol collaboration merck equity method accounting discuss income expense net include high net interest expense income expense net include million income relate sale company marketing right suboxone subutex sublingual tablet treatment opioid dependence income expense net footnote additional information special charge component special charge follow dollar million employee termination cost asset impairment loss litigation charge consent decree charge table content employee termination cost august company announce global workforce reduction initiative phase initiative verp united states program eligible employee united states december elect early retirement receive enhance retirement benefit approximately employee elect retire program approximately employee retire near yearend approximately employee stagger retirement date future total cost program estimate million comprise increase pension cost million increase postretirement health care cost million vacation payment million cost relate accelerate vest stock grant million employee stagger retirement date future amount recognize special charge employee remain service period delay expense recognition follow guidance statement financial accounting standard sfas accounting cost associate exit disposal activity amount recognize program million amount expect recognize million million respectively expect cash expenditure associate program million million respectively include employee termination cost table million employee severance cost december company announce target overall reduction payroll relate expense percent exclude payroll expense associate customercontact employee employee dedicated fulfilling company fda consent decree obligation target include saving realize verp company expect incur additional employee termination cost associate achieve goal reduce payroll relate expense saving expect realize action approximate million annually company expect reinvest significant portion saving expand sale force maximize zetia ezetimibesimvastatin opportunity support nasonex remicade intron franchise asset impairment loss asset impairment loss recognize accordance sfas goodwill intangible asset sfas accounting impairment disposal longlive asset asset impairment loss relate follow company cease production certain product produce manufacture site operate fda consent decree company announce closure manufacturing site england manufacturing site england substantially cease sale affect product table content material asset impairment loss million base discount cash flow recognize related facility equipment site company cease marketing license cancer therapy drug sell country outside united states sale product decline material introduction compete product result decline market share company drug point management conclude long practical continue participate marketplace asset impairment loss million base discount cash flow recognize related intangible asset company sun care brand compete highend segment overall sun care market large cosmetic company enter market segment sale company brand decline company acquire brand portion purchase price allocate trade base fair value time company perform periodic review value assign intangible asset connection review impairment loss million relate trade recognize base discount cash flow reflect change market condition brand acquire sale sun care brand material litigation charge litigation reserve increase million million respectively primarily result investigation companys sale marketing practice legal environmental regulatory matter footnote additional information consent decree charge provision million recognize payment federal government consent decree consent decree footnote additional information table content summary select special charge follow summarize activity account related employee termination cost asset impairment loss amount million employee asset termination impairment cost loss special charge impairment writeoff credit retirement benefit plan liability cash disbursement special charge accrual balance dec balance december employee termination cost represent value stock grant million distribute yearend severance accrue vacation payment pay million equity income cholesterol joint venture effective company present collaboration merck jointly develop market zetia ezetimibesimvastatin combination follow equity method accounting method company record share operating profit share research development cost equity income cholesterol joint venture include line year company share operating profit million million milestone receipt share research development costs million noted company incur substantial cost sell cost reflect equity income cholesterol joint venture bear entirely company zetia launch united states international market november additional market launch occur date global sale zetia million prior venture research development phase company share research development expense million million respectively report research development statement consolidated operation net lossincome net lossincome loss million versus income billion billion respectively net lossincome include special charge million describe net income include million pretax provision increase litigation reserve include million pretax provision consent decree payment provision include special charge effective tax rate year effective tax rate percent exclude million nontax deductible provision increase litigation reserve effective tax rate percent company reduce effective tax rate decrease profit primarily united states additional information income taxis footnote note consolidated financial statement impact potential early termination swap discuss liquidity financial resource result high effective tax rate lossearning common share dilute lossearning common share decrease loss increase percent earning weaken dollar foreign currency increase growth earning common share dilute earning share reflect favorable exchange impact respectively company advise trend earning view aforementioned special charge impact yeartoyear change foreign exchange rate table content liquidity financial resource background follow background information useful reader understand current state company liquidity financial resource december approximately percent cash cash equivalent shortterm investment show accompany balance sheet hold wholly own foreignbased subsidiary time substantially debt show accompany balance sheet owe parent company wholly own usbased subsidiary year prior geographic disparity location fund location debt pivotal issue company material decline earning follow loss marketing exclusivity claritin united states geographic disparity take importance cash cash equivalent plus shortterm investment exceed total debt december billion fund hold foreign base subsidiary cash need usbased subsidiary result income tax payment income tax payment depend number factor include fund operation generate taxable profit loss operation generate tax loss primarily decline claritin sale continue investment research development entire tax loss recoup taxis pay previous year carryback benefit management expect operation generate tax loss portion loss expect recoup taxis pay previous year current law carryback benefit exhausted expect loss excess recoup taxis pay previous year available reduce taxable income future carryforward benefit operation generate loss recoup taxis pay previous year company choice use carryforward benefit future year utilize loss absorb taxable distribution cash asset hold foreignbased subsidiary absorb operating loss manner allow portion asset hold foreignbased subsidiary available use operation income tax payment discuss company expect finance portion cash need possibly access fund hold foreign base subsidiary fund company expect access represent foreign earning generate company expect incur additional income taxis access fund taxable distribution absorb expect operating table content loss describe company additional taxable distribution fund hold foreignbased subsidiary operation company trigger credit rating downgrade provision certain financing arrangement company incur additional income taxis additional distribution foreignbase subsidiary exceed operating loss discussion cash flow cash provide operating activity total million million million cash provide operating activity decline low sale claritin low sale product intron franchise high manufacturing cost portion cash flow impact low sale mitigate collection account receivable follow decline sale cash provide operating activity include second payment million relate fda consent decree previous filing company report possibly cash provide operating activity sufficient fund work capital capital expenditure dividend item remain thencurrent level response decline sale earning likelihood decline company announce august reduction quarterly dividend cent cent common share action save approximately million quarter begin fourth quarter day company announce accelerate intensify costcutte action include global workforce reduction effort show statement consolidated cash flow cash need work capital capital expenditure dividend exceed cash operation excess cash need cash generation occur entirely operation deficit approximately million foreign operation generate cash excess cash need company borrow additional fund united states finance operation continue accumulate cash foreignbase subsidiary management expect foreign operation generate cash operation cash need exclude potential payment arise litigation investigation discuss deficit expect decline dividend payment approximately million company expect receive tax refund excess million carryback benefit describe approximately million cash available december pay commercial paper balance fund operation discussion consideration payment arise matter describe legal environmental regulatory matter footnote include financial statement report particular company accrue material amount respect investigation conduct attorney office pennsylvania table content massachusetts respect dispute irs time management estimate ultimate amount time potential payment certainty payment increase cash need operation necessitate additional financing repatriation fund hold foreignbased subsidiary combination matter affect company credit rating ability access commercial paper company current cash management strategy capital structure remain unchanged management expect cash hold foreign base subsidiary debt owe usbased subsidiary increase management process evaluate present strategy structure appropriate light increase debt level change portfolio company product management believe company possess sufficient financial resource meet financial need company excess billion cash cash equivalent shortterm investment albeit hold foreignbased subsidiary sizable line credit commercial bank describe management believe company continue access capital market borrowing credit facility november company issue billion aggregate principal percent senior unsecured note billion aggregate principal percent senior unsecured note proceed offer billion general corporate purpose include repay commercial paper outstanding united states issuance note rate moodys investor service moodys creditwatch negative implication standard poor interest rate payable note subject adjustment rating assign note moodys downgrade respectively interest rate payable series note increase financial instrument commitment footnote include financial statement report additional information company revolve credit facility total billion recently negotiate facility september billion day credit facility major financial institution draw united states facility mature september facilities syndicate financial institution provide million draw united states repayment second multi currency facility million draw united states internationally maturity date december fund draw facility december shortterm borrowing total million approximately percent outstanding commercial paper commercial paper rating discuss significantly affect company ability issue roll outstanding commercial paper borrowing time ability commercial paper issuer table content company shortterm credit rating moodys andor fitch rating fitch issue roll outstanding commercial paper time company high shortterm credit rating addition total commercial paper capacity available issuer typically high rate company company maintain sizable line credit commercial bank cash shortterm investment hold foreignbased subsidiary serve alternative source liquidity support commercial paper program credit rating december lower company corporate credit longterm debt rating say outlook rating negative note weakening company intron franchise expect decline earning cash flow change company shortterm corporate credit commercial paper rating lower july january place company corporate credit rating shortterm credit rating senior unsecured debt rating creditwatch negative implication february downgrade company senior unsecured debt rating time lower company shortterm corporate credit commercial paper rating remove company creditwatch outlook remain negative october moodys lower company corporate credit rating lower commercial paper rating follow rating action moodys remove company watchlist revise rating outlook stable negative moodys state credit rating assume modest outflow settle outstanding litigation acquisition large payment associate litigation proceeding acquisition activity place pressure rating andor outlook november fitch downgrade company senior unsecured bank loan rating commercial paper rating companys rating outlook remain negative announce downgrade fitch note sale decline company lead product franchise intron franchise greater anticipate concerned total company growth reliant performance key growth driver zetia remicade near term table content financial arrangement contain credit rating downgrade trigger company separate arrangement enable manage cash flow subsidiary foreignbase subsidiary arrangement employ interest rate swap arrangement similar credit rating downgrade trigger allow counterparty early termination credit rating downgrade trigger require company maintain longterm debt rating moodys sps moodys current credit rating specify minimum result counterparty interest rate swap elect early termination follow specify period describe arrangement utilize longterm interest rate swap contract foreignbase subsidiary bank subsidiary bank contract equal offset term cover master netting arrangement contract involve foreignbased subsidiary permit subsidiary prepay portion future obligation bank contract involve subsidiary permit bank prepay portion future obligation subsidiary interest pay prepay balance party market rate prepayment total billion contract december prepay amount net preparation consolidated balance sheet accordance financial accounting standard board fasb interpretation offset amount relate certain contract arrangement provide event company fail maintain require minimum credit rating counterparty terminate transaction designate early termination date early month follow date notice terminate notice give early termination consequence discuss occur end threeyear period early termination require repayment prepaid amount repayment occur original tax jurisdiction prepay amount accordingly early termination require company subsidiary repay billion bank bank repay billion company foreignbase subsidiary financial impact early termination depend manner extent company decide finance repayment obligation company finance entire obligation obtain short longterm finance united states case cash debt increase equal amount consolidated balance sheet company ability finance obligation swap depend company credit rating business operation market condition time financing contemplate alternatively company repatriate united states fund receive foreignbase subsidiary repatriate fund income tax consequence depend primarily profitability operation tax accrue future earning result company report high effective tax rate currently operation generate tax loss future tax table content loss insufficient absorb potential tax company repatriate fund receive foreignbase subsidiary state termination transaction occur early month follow date company receive termination notice counterparty accordingly early termination imminent fact alternative course action available company event early termination potential early termination impact current liquidity financial resource second arrangement utilize longterm interest rate swap contract enter notional principal million second enter notional principal million term contract enable company sell right receive payment retain obligation payment parent company sell right receive payment contract foreignbase subsidiary return approximately million fair value intercompany transaction eliminate preparation consolidated financial statement internal revenue service assert transaction sale loan additional income taxis company expect litigate matter describe legal environmental regulatory matter footnote financial statement contract allow counterparty effectively terminate transaction company fail maintain require minimum credit rating day restore require minimum credit rating company credit rating fell require minimum credit rating february unlikely company restore credit rating allot time early termination contract credit rating downgrade likely result parent company reacquire right receive payment foreignbase subsidiary terminate transaction counterparty net basis reacquisition right receive payment swap contract occur parent company buy right fair market value foreignbase subsidiary dividend right parent company buy right necessitate funding united states company currently estimate approximately million case cash debt increase equal amount consolidated balance sheet alternatively foreignbase subsidiary dividend right parent company result additional income taxis presently operation company generate tax loss loss expect exceed value intercompany dividend necessary reacquire right result event early termination management alternative reacquire right terminate transaction counterparty materially impact liquidity financial resource accordingly management view early termination arrangement material event impact current liquidity financial resource table content contractual obligation payment period company know contractual obligation december follow dollar million payment period total year year year year longterm debt obligation operating lease obligation purchase obligation advertising contract research contract capital expenditure commitment purchase order record longterm liability total longterm debt obligation include million aggregate principal percent senior unsecured note million aggregate principal percent senior unsecured note financial instrument commitment footnote note consolidated financial statement additional information research contract include potential milestone payment payment contingent occurrence certain event table exclude research contract cancelable company penalty open purchase order consist cancelable noncancelable inventory expense item caption include obligation base undiscounted amount estimate payment certain company pension plan hold qualified asset estimate payment company defer compensation plan environmental matter company responsibility environmental cleanup state local federal law include comprehensive environmental response compensation liability act commonly know superfund environmental expenditure base information currently available anticipate material impact company additional information legal environmental regulatory matter footnote note consolidated financial statement table content additional factor influence operation united states company pharmaceutical product subject increasingly competitive pricing manage care group institution government agency group seek price discount international market company operate environment governmentmandate cost containment program market company pharmaceutical manufacturer require provide statutorily define rebate government agency order participate medicaid veterans health care program governmentfunde program government place restriction physician prescription level patient reimbursement emphasize great use generic drug enact acrosstheboard price cut method control cost company unable predict final form time future domestic international governmental health care initiative include passage law permit importation pharmaceutical united states effect operation cash flow reasonably estimate similarly effect operation cash flow decision government entity manage care group group concern formulary pharmaceutical reimbursement policy reasonably estimate company predict net effect medicare prescription drug benefit market sale program effect company lead drug cover medicare temodar integrilin intron relatively small portion sale medicare population clarinex hepatitis franchise company experience expand utilization zetia new drug company pipeline great consequence company legislation impact pricing rebate discount significant portion net sale major pharmaceutical health care product distributor major retail chain united states consequently net sale quarterly growth comparison affect fluctuation buy pattern major distributor retail chain trade buyer fluctuation result seasonality pricing wholesaler buying decision factor market pharmaceutical product competitive company operation affect technological advance competitor industry consolidation patent grant competitor new product competitor generic competition company product mature addition patent position increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product effect operation competitive factor patent dispute predict note legal environmental regulatory matter footnote include financial statement report company sue drug manufacturer marketing seek market certain form generic loratadine prior expiration company compound patent desloratadine case company file suit federal court seek rule applicable abbreviate new drug application anda paper new drug application submission propose marketing generic prescription otc product table content constitute infringement company patent challenge patent merit compound patent loratadine expire june market exclusivity claritin expire december patent cover compound desloratadine formulation thereof method treatment desloratadine relate claritin set expire april month market exclusivity attach end desloratadine patent relate claritin expire october sixmonth period exclusivity grant company conduct pediatric clinical trial request fda august federal district court new jersey rule motion summary judgment find certain desloratadine compound patent claim company believe protect claritin anticipate prior patent valid august district court decision sustain appellate court october appellate court deny company petition rehear ruling action defendant infringement desloratadine compound patent manufacturer loratadine proceed company assert andas file manufacturer generic version claritind hour infringe company patent cover claritind hour company settle litigation impax andrx october licensed patent november company announce formulation claritin brand nondrowsy allergy product approve original prescription strength fda otc medicine treatment allergy company inform fda new drug application nda claritin formulation indication allergy hive transfer fdas pulmonary division office drug evaluation division overthecounter drug product office drug evaluation company launch otc claritin united states december december compete otc loratadine product launch united states quarter company begin face additional privatelabel competition otc claritin line nonsedate antihistamines initial day period exclusivity expire otc generic competitor company continue market clarinex desloratadine tablets treatment allergic rhinitis combine indication seasonal allergic rhinitis indication perennial allergic rhinitis treatment chronic idiopathic urticaria hive unknown cause ability company capture maintain market share clarinex otc claritin market depend number factor include additional entrant market allergy treatment clinical differentiation clarinex allergy treatment perception extent differentiation marketplace pricing differential otc claritin clarinex allergy treatment generic otc loratadine erosion rate otc claritin clarinex sale entry additional generic otc loratadine product brand secondgeneration antihistamine switch prescription otc status clarinex experience intense competition prescription allergy market prescription allergy market shrink otc switch claritin table content december company implement new marketing effort address market share performance clarinex switch claritin otc status introduction compete otc loratadine result rapid sharp material decline claritin sales united states company result operation sale prescription claritin product million percent company consolidated global sale billion percent sale clarinex united states abroad materially adversely affect presence generic otc loratadine otc claritin light factor describe management believe company december introduction otc claritin introduction compete otc loratadine product december additional entrant generic otc loratadine product market rapid sharp material adverse effect company result operation likely continue indeterminate period time disclose filing securities exchange commission sec note legal environmental regulatory matter footnote include financial statement report drug manufacturer submit andas fda seek market generic form rebetol ribavirin capsules united states expiration company patent cover ribavirin formulation company sue manufacturers federal court infringement company enter separate licensing agreement river pharmaceutical llc river geneva pharmaceuticals inc geneva teva pharmaceuticals usa inc teva settle patent litigation company river geneva teva grant company nonexclusive nonsublicensable license company ribavirin patent settlement affect river genevas tevas report patent litigation ribapharm inc subsidiary valeant pharmaceutical international ribapharm relate ribavirin patent litigation dismiss defendant motion summary judgment july ribapharm appeal summary judgment decision ribapharm petitioned fda deny approval river geneva teva products fda act ribapharm petition generic form ribavirin expect enter market assume fdas approval generic ribavirin rebetol patent material company business sale rebetol million pegintron rebetol combination therapy hepatitis contribute substantially sale fourth quarter compete pegylate interferonbased combination product include brand ribavirin receive regulatory approval major market include united states overall market share intron franchise decline sharply reflect new market competition management believe ability pegintron rebetol combination therapy maintain market share continue adversely affect new competition hepatitis marketplace october merckscheringplough pharmaceutical announce fda approve zetia ezetimibe use statin treatment elevate cholesterol level march company announce ezetimibe ezetrol table content market europe successfully complete european union mutual recognition procedure mrp completion mrp process member states iceland norway grant national marketing authorization unify labeling ezetrol ezetrol launch international market merckscheringplough partnership pursue development marketing oncedaily tablet combine ezetimibe simvastatin zocor merck cholesterolmodifye medicine uncertainty inherent government regulatory approval process include thing delays approval new product formulation indication affect company operation effect regulatory approval process operation predict company subject jurisdiction national state local regulatory agency subject potential administrative action particular importance fda united states jurisdiction company business administer requirement cover testing safety effectiveness approval manufacturing labeling marketing company product time time agency include fda require company address manufacturing advertising label regulatory issue note relate company current manufacturing issue failure comply governmental regulation result delay release product seizure recall product suspension revocation authority necessary production sale product discontinuance product fine civil criminal sanction result material adverse effect company financial position result operation additional information government regulation affect future result provide item business company annual report fiscal year end december additional information cautionary factor affect future result provide caption cautionary factor affect future result cautionary statement private security litigation reform act management discussion analysis operation financial condition note consent decree footnote include financial statement report company announce reach agreement fda consent decree resolve issue involve company compliance current good manufacturing practice certain manufacturing facility new jersey puerto rico district court district new jersey approve enter consent decree term consent decree company agree pay total million government equal installment million installment pay second installment pay second quarter previously report company accrue million provision consent decree fourth quarter consent decree require company complete number action event certain action agree consent decree satisfactorily complete time fda assess payment deadline miss consent decree require company develop table content submit fdas concurrence comprehensive cgmp work plan company manufacture facility new jersey puerto rico cover decree company receive fda concurrence propose cgmp work plan cgmp work plan contain number significant step timely satisfactory completion subject payment business day deadline miss payment exceed million million year payment subject overall cap million connection discussion fda company cgmp work plan pursuant term decree company fda enter letter agreement date april letter agreement company fda agree extend month time period company incur payment describe respect certain significant step propose date december letter agreement increase yearly overall cap payment describe addition decree require company complete program revalidation finish drug product bulk active pharmaceutical ingredient manufacture covered manufacturing facility company require consent decree complete revalidation program bulk active pharmaceutical ingredient september finish drug december general timely satisfactory completion revalidation subject payment business day deadline miss subject cap describe product schedule revalidation certify validate date validation schedule fda assess payment percent net domestic sale uncertified product validation certify general product schedule revalidation consent decree certify month schedule date company cease production product certification obtain completion significant step work plan completion revalidation program subject thirdparty expert certification accept fda consent decree provide company believe able meet deadline company right show good cause request extension deadline connection cgmp work plan revalidation program guarantee fda grant request company believe significant progress meet obligation consent decree possible company fail complete significant step revalidation prescribe deadline party expert certify completion significant step revalidation fda disagree expert certification significant step revalidation case possible fda assess payment describe company expense payment assess decree incur table content addition failure meet term consent decree result delay approval new product seizure recall product suspension revocation authority necessary production sale product fine civil criminal sanction april company receive notice false claim act complaint bring individual purport act behalf government approximately pharmaceutical company district court northern district texas complaint allege pharmaceutical company include company defraud united states sale federal governmental agency drug allegedly manufacture manner comply current good manufacturing practice company defendant file motion dismiss action july company subject pharmacovigilance reporting requirement country jurisdiction include united states european union member states requirement differ jurisdiction jurisdiction include requirement report adverse event occur patient particular drug order alert manufacturer drug governmental agency potential problem pharmacovigilance inspection official british french medicine agency conduct request european agency evaluation medicinal product emea deficiency report process identify company take urgent action rectify deficiency quickly possible company know action emea national authority response finding possible action include inspection demand improvement report system criminal sanction company andor responsible individual change condition marketing authorization company product describe specifically legal environmental regulatory matter footnote include financial statement report reader report direct pricing sale marketing program arrangement relate business practice company participant health care industry increase scrutiny federal state regulatory investigative prosecutorial administrative entity entity include department justice attorney office office inspector general department health human service fda federal trade commission ftc state attorney general office health care law certain governmental entity operate include federal state antikickback statute statutory common law false claim law construe broadly court permit government entity exercise significant discretion event governmental entity believe wrongdoing occur institute civil criminal proceeding institute resolve unfavorably subject company substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program company predict investigation affect marketing practice table content sale result material adverse effect company financial condition result operation critical accounting policy follow accounting policy consider significant change certain judgment assumption inherent policy affect company financial statement accrual rebate sale pharmaceuticals united states provision income taxis undistribute foreign earning intercompany pricing matter impairment intangible asset account legal regulatory matter pharmaceutical product sell direct purchaser wholesaler retailer certain health maintenance organization company invoice entity product ship addition company commercial rebate discount arrangement certain indirect purchaser market participant manage care organization indemnify beneficiary health plan pharmaceutical cost pharmacy benefit manager base purchase utilization company product company governmental rebate obligation certain federal state program purpose revenue recognition company end quarter estimate applicable commercial governmental rebate pay product sell quarter net estimate amount total direct sale rebate estimate base term historical experience trend analysis project market condition market serve case governmental rebate program company payment involve interpretation relevant statute regulation interpretation subject challenge change interpretive guidance governmental authority result challenge change affect estimate governmental rebate amount ultimately sufficient satisfy company obligation additional information governmental inquiry focus calculation rebate contain legal environmental regulatory matter footnote note consolidated financial statement report addition possible result governmental challenge change interpretive guidance actual rebate materially exceed amount accrue december taxis provide approximately billion undistributed earning foreign subsidiary management determine asset associate earning permanently reinveste company overseas operation future event require certain asset associate earning repatriate united states additional tax provision necessary regard income taxis certain company consolidate subsidiary manufacture pharmaceutical ingredient facility locate lowtax jurisdiction manufacturing subsidiary sell pharmaceutical ingredient consolidate subsidiary manufacture final sale customer tax authority world table content challenge price charge manufacturing subsidiary management believe pricing base sound economic fact circumstance successful challenge tax authority management believe unlikely result additional income tax payment materially excess amount accrue intangible asset represent capitalize cost purchase goodwill patent license form intellectual property total million december value asset subject continue scientific medical marketplace uncertainty example market pharmaceutical product withdraw market safety reason marketing product occur pronounce warning amount capitalize product need reduce impairment event give rise impairment inherent risk pharmaceutical industry predict management regularly review intangible asset possible impairment discuss special charge section company recognize asset impairment loss intangible asset asset impairment loss recognize intangible asset relate cancer therapy drug scientific advancement intangible asset relate trade sun care product marketplace competition management judgment estimate require account legal regulatory matter particular company recognize estimate minimum liability connection certain government investigation sale marketing activity legal environmental regulatory matter footnote note consolidated financial statement market risk disclosure company expose market risk primarily change foreign currency exchange rate less extent interest rate equity price follow describe nature risk foreign currency exchange risk company subsidiary country sale outside united states account approximately percent global sale virtually sale denominate currency local country company report profit cash flow expose change exchange rate change foreign exchange rate increase sale percent increase diluted earning common share date management deem cost effective engage formulabase program hedge profit cash flow foreign operation derivative financial instrument companys foreign subsidiary purchase significant quantity inventory payable dollar manage level inventory relate payable rate inventory turnover provide level protection adverse change exchange rate risk adverse exchange rate change mitigate fact company foreign operation widespread table content addition point time company foreign subsidiary hold financial asset liability denominate currency dollar financial asset liability consist primarily shortterm thirdparty intercompany receivables payable change exchange rate affect financial asset liability gain loss arise translation significantly affect net income occasion company derivative hedge specific shortterm risk situation involve foreign currency exposure derivative transaction material interest rate equity price risk financial asset expose change interest rate andor equity price debt equity security hold nonqualified trust employee benefit asset total million december longterm nature liability trust asset fund company exposure market risk deem low financial obligation expose variability interest expense shortterm borrowing company maintain cash cash equivalent portfolio excess shortterm borrowing accordingly company net exposure change interest rate relate financial obligation company longterm debt outstanding percent decrease interest rate change fair value debt million company expect refund debt interest rate swap company utilize interest rate swap international cash management strategy additional information financial instrument commitment footnote note consolidated financial statement swap subject company moderate degree market risk company account swap fair value accounting change fair value record earning fair value swap liability million december liability million december estimate percent change interest rate structure change fair value swap million table content cautionary factor affect future result cautionary statement private security litigation reform act management discussion analysis financial condition result operation section report write report oral statement time time company contain forwardlooke statement mean security litigation reform act forwardlooke statement relate expectation forecast future event use word anticipate believe estimate expect forecast project intend plan potential word term similar meaning connection discussion potential future event circumstance future operate financial performance identify forwardlooke statement fact relate strictly historical current fact particular forwardlooking statement include statement relate future action ability access capital market prospective product status product approval future performance result current anticipate product sale effort development program expense program reduce expense cost saving verp outcome contingency litigation investigation growth strategy financial result forwardlooke statement publication turn wrong actual result vary materially guarantee performance scheringplough stock scheringplough assume obligation update forwardlooke statement factor cause actual result differ scheringplough forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know possible predict identify factor include follow significant portion net sale major pharmaceutical health care product distributor major retail chain united states consequently net sale quarterly growth comparison affect fluctuation buy pattern major distributor retail chain trade buyer fluctuation result seasonality pricing wholesaler buying decision factor competitive factor include technological advance attain competitor patent grant competitor new product competitor come market new indication competitive product generic prescription otc competition scheringplough product mature patent expire product increase pricing pressure united states abroad manage care organization institution government agency programs united states development consolidation customer increase pricing pressure result customer great influence prescription decision formulary decision policy government law regulation change law regulation affect domestic international operation include health care reform initiative drug importation legislation united states state federal level table content country law regulation relate trade antitrust monetary fiscal policy taxis price control possible nationalization patent position highly uncertain patent dispute unusual adverse result patent dispute preclude commercialization product negatively impact sale exist product result injunctive relief payment financial remedy uncertaintie fda approval process regulatory approval review process country include limitation delay approval new product failure meet good manufacturing practice establish fda governmental authority result delay approval product release product seizure recall product suspension revocation authority necessary production sale product fine civil criminal sanction resolution manufacturing issue fda discuss scheringplough subject substantial risk uncertaintie risk uncertainty include time scope duration resolution manufacturing issue depend ability scheringplough assure fda quality reliability manufacturing system control extent remedial prospective obligation undertake scheringplough difficulty product development pharmaceutical product development highly uncertain product appear promise development fail reach market numerous reason found ineffective harmful effect clinical preclinical testing fail receive necessary regulatory approval turn economically feasible manufacturing cost factor precluded commercialization proprietary right efficacy safety concern respect market product scientifically justified leading recall withdrawal decline sale major product claritin clarinex intron pegintron rebetol capsules remicade nasonex account material portion scheringplough revenue major product subject problem loss patent protection otc availability company product competitive product disclose claritin current potential otc competition previously unknown effect new effective treatment introduce generic availability competitive product product discontinue reason impact revenue significant information important new product zetia important product pipeline impact future revenue unfavorable outcome government local federal domestic international investigation litigation product pricing product liability claim litigation environmental concern preclude commercialization product negatively affect profitability exist product materially adversely impact scheringplough financial condition result operation contain condition impact business operation exclusion government reimbursement program economic factor scheringplough control include change inflation interest rate foreign currency exchange rate table content instability disruption destruction significant geographic region location manufacture facility distribution facility customer regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease change tax law include change relate taxation foreign earning change accounting standard promulgate american institute certify public accountant financial accounting standard board sec public company accounting oversight board require significant change scheringplough accounting practice detail discussion risk uncertainty scheringplough past future sec filings item quantitative qualitative disclosure market risk market risk disclosure set forth item management discussion analysis operation financial condition result operation table content item financial statement supplementary datum index financial statement statement consolidated operation year end december statement consolidated cash flow year end december consolidated balance sheet december statement consolidated shareholder equity year end december note consolidated financial statement independent auditor report table content scheringplough corporation subsidiary statement consolidated operation year end december amount million share figure net sale cost sale sell general administrative research development income expense net special charge equity income cholesterol joint venture lossincome income taxis income taxis net lossincome dilute lossearning common share basic lossearning common share note consolidated financial statement table content scheringplough corporation subsidiary statement consolidated cash flow year end december amount million operating activity net lossincome depreciation amortization account receivable inventory prepaid expense asset account payable liability special charge net cash provide operating activity invest activity capital expenditure purchase investment reduction investment net net cash investing activity financing activity cash dividend pay common shareholder common share repurchase net change shortterm borrowing issuance longterm debt net net cash provide financing activity effect exchange rate cash cash equivalent net increase cash cash equivalent cash cash equivalent begin year cash cash equivalent end year note consolidated financial statement table content scheringplough corporation subsidiary consolidate balance sheet december amount million share figure asset current asset cash cash equivalent shortterm investment account receivable allowance inventory defer income taxis prepaid expense current asset total current asset property cost land building improvement equipment construction progress total accumulate depreciation property net goodwill intangible asset net asset total asset table content december liabilities shareholder equity current liability account payable shortterm borrowing current portion longterm debt foreign state income taxis accrue compensation accrue liability total current liability longterm liability longterm debt defer income taxis longterm liability total longterm liability shareholder equity prefer share authorize share par value issue common share authorize share par value issue paidin capital retain earning accumulate comprehensive income total treasury share cost total shareholder equity total liability shareholder equity note consolidated financial statement table content scheringplough corporation subsidiary statement consolidated shareholder equity accumulate total compre share common paidin retain treasury hensive holder amount million share capital earning share income equity balance january comprehensive income net income foreign currency translation realize gain reclassify income net tax total comprehensive income cash dividend common share stock incentive plan common share repurchase balance december comprehensive income net income foreign currency translation minimum pension liability net tax realize gain reclassify income net tax total comprehensive income cash dividend common share stock incentive plan balance december comprehensive income net loss foreign currency translation minimum pension liability net tax unrealized gain investment available sale net tax total comprehensive income cash dividend common share stock incentive plan balance december note consolidated financial statement table content note consolidated financial statement dollar million share figure summary significant accounting policy principle consolidation consolidated financial statement include scheringplough corporation subsidiary company intercompany balance transaction eliminate certain prior year amount reclassify conform current year presentation use estimate preparation financial statement conformity generally accept accounting principle require management estimate use assumption affect certain report amount disclosure actual amount differ cash cash equivalent cash cash equivalent include operate cash highly liquid investment generally original maturity month inventory inventory value low cost market cost determine lastin firstout method substantial portion inventory locate united states cost inventory determine firstin firstout method depreciation depreciation provide estimate useful life property generally use straightline method average useful life year building year build improvement year equipment depreciation expense respectively foreign currency translation net asset company foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation adjustment account include comprehensive income remain foreign subsidiary nonmonetary asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include income exchange gain loss arise translate intercompany balance longterm investment nature record foreign currency translation adjustment account exchange gain loss include income table content accumulate comprehensive income accumulate comprehensive income primarily consist accumulate foreign currency translation adjustment account unrealize gain loss security classify statement financial accounting standard sfas purpose available sale minimum pension liability adjustment component accumulate comprehensive income december accumulate foreign currency translation accumulate unrealized gain loss investment available sale net tax minimum pension liability net tax total gross unrealized pretax gain unrealize loss immaterial gross unrealized gain loss immaterial revenue recognition revenue sale product recognize good ship customer reliable estimate product return reliable estimate product return business condition permit company reasonable estimate expect demand follow approval claritin overthecounter otc product fourth quarter revenue sale prescription form claritin recognize product fill patient prescription reliable estimate product return time shipment expiration initial day period exclusivity generic competitor otc form claritin company experience additional privatelabel competition result revenue sale otc claritin recognize time shipment extent company reasonable estimate product return provision discount rebate record period relate sale record purpose revenue recognition end quarter company estimate applicable commercial governmental rebate pay product sell reduce record sale estimate amount rebate estimate base term historical experience trend analysis project market condition market serve table content earning common share dilute earning common share compute divide income sum weightedaverage number common share outstanding plus dilutive effect share issuable defer stock unit exercise stock option dilute loss common share exclude effect share issuable defer stock unit exercise stock option include effect decrease loss share basic earning common share compute divide income weightedaverage number common share outstanding share calculate basic diluted earning common share reconcile follow share million average share outstanding basic earning share dilutive effect option defer stock unit average share outstanding diluted earning share equivalent million million million common share issuable company stock incentive plan exclude computation dilute earning share december respectively effect antidilutive goodwill effective january company adopt sfas goodwill intangible asset sfas eliminate requirement amortize goodwill instead require periodic testing goodwill impairment goodwill impaired write estimate fair value company perform require annual goodwill impairment test find record goodwill impair accordingly adoption sfas result adjustment record goodwill goodwill amortization expense dilute basic earning common share unchanged goodwill amortization exclude net income pro forma basis company goodwill primarily related animal health business intangible asset component balance sheet caption intangible asset net follow december december gross gross carrying accumulate carry accumulate amortization net amortization net patent license trademark total intangible asset table content intangible asset amortize straightline method respective useful life company pay respectively patent licensing right cost amortize approximately year residual value intangible asset estimate zero amortization expense relate intangible asset respectively intangible asset review determine recoverability compare carry value expect undiscounted future cash flow event circumstance warrant review year amortization expense year estimate approximately year base intangible asset record december accounting stockbase compensation company account stock compensation arrangement intrinsic value method intrinsic value method difference employee pay company stock acquire company incentive plan stock fair value date grant charge expense employee pay company grantdate fair value stock option expense record stock option alternatively employee pay stock issue deferred stock unit grant grant date fair value record expense follow table reconcile net lossincome lossearning common share eps report pro forma net lossincome ep company expense grantdate fair value stock option defer stock unit permit sfas accounting stockbase compensation pro forma amount representative initial impact adopt sfas amend permit alternative method adoption net lossincome report add expense include report net income defer stock unit net tax deduct pro forma expense stock option defer stock unit charge net income net tax pro forma net lossincome fair value method diluted lossearning share dilute lossearning share report pro forma diluted lossearning share fair value method basic lossearning share basic lossearning share report pro forma basic lossearning share fair value method table content weightedaverage fair value option grant respectively fair value estimate blackschole option pricing model base follow assumption dividend yield volatility riskfree interest rate expect term option year recently issue accounting standard november fasb issue fasb interpretation guarantor accounting disclosure requirement guarantee include indirect guarantee indebtedness normal course business company issue guarantee party accordingly interpretation effect company financial statement april fasb issue sfas amendment statement derivative instrument hedge activity adoption sfas effect company financial statement fasb issue sfas account certain financial instrument characteristic liability equity require certain financial instrument classify liability asset circumstance adoption sfas effect company financial statement december fasb issue fasb interpretation revise consolidation variable interest entity fin adoption fin effect company financial statement january fasb issue staff position fas title accounting disclosure requirement relate medicare prescription drug improvement modernization act fsp act sign law december introduce prescription drug benefit medicare federal subsidy certain condition sponsor retiree health care benefit plan presently authoritative guidance accounting subsidy issue company elect onetime deferral accounting effect act permit fsp deferral continues apply authoritative guidance account federal subsidy issue special charge component special charge follow employee termination cost asset impairment loss litigation charge consent decree charge table content employee termination cost august company announce global workforce reduction initiative phase initiative voluntary early retirement program united states program eligible employee united states december elect early retirement receive enhance retirement benefit approximately employee elect retire program approximately employee retire near yearend approximately employee stagger retirement date future total cost program estimate comprise increase pension cost increase postretirement health care cost vacation payment cost related accelerate vest stock grant employee stagger retirement date future amount recognize special charge employee remain service period delay expense recognition follow guidance sfas accounting cost associate exit disposal activity amount recognize program amount expect recognize respectively asset impairment loss asset impairment loss recognize accordance sfas goodwill intangible asset sfas accounting impairment disposal long live asset asset impairment loss relate follow company cease production certain product produce manufacture site operate fda consent decree company announce closure manufacturing site england manufacturing site england substantially cease sale affect product material asset impairment loss base discount cash flow recognize related facility equipment site company cease marketing license cancer therapy drug sell country outside united states sale product decline material introduction compete product result decline market share company drug point management conclude long practical continue participate marketplace asset impairment loss base discount cash flow recognize related intangible asset company sun care brand compete highend segment overall sun care market large cosmetic company enter market segment sale company brand decline company acquire brand portion purchase price allocate trade base fair value time company perform periodic review value assign intangible asset connection review impairment loss relate trade recognize base discount cash flow reflect change market condition brand acquire sale sun care brand material table content litigation charge litigation reserve increase respectively primarily result investigation companys sale marketing practice legal environmental regulatory matter footnote additional information consent decree charge provision recognize payment federal government consent decree consent decree footnote additional information summary select special charge follow summarize activity account related employee termination cost asset impairment loss employee asset termination impairment cost loss special charge impairment writeoff credit retirement benefit plan liability cash disbursement special charge accrual balance dec balance december employee termination cost represent value stock grant distribute yearend severance accrue vacation payment pay financial instrument commitment sfas amend require derivative record balance sheet fair value statement provide effective portion qualify cash flow hedge recognize income hedge item affect income change fair value derivative qualify fair value hedge change fair value hedge risk recognize occur change fair value derivative qualify hedge treatment ineffective portion qualifying hedge recognize income occur risk policy objective company expose market risk primarily change foreign currency exchange rate less extent interest rate equity price change time time company hedge selective foreign currency risk derivative generally management deem cost effective engage formulabase program hedge profit cash flow foreign operation derivative financial instrument companys foreign subsidiary purchase significant quantity inventory payable dollar manage level inventory relate payable rate inventory turnover provide level protection adverse change exchange rate furthermore risk adverse exchange rate change mitigate fact company foreign operation widespread limited basis company hedge selective exposure interest rate risk table content company mitigate credit risk derivative instrument deal counterpartie consider financially sound accordingly company anticipate loss nonperformance company enter derivative instrument generate trading profit table present carry value estimate fair value companys financial instrument include derivative financial instrument estimate fair value determine base market price available dealer quote december december carry estimate carry estimate value fair value value fair value asset cash cash equivalent shortterm investment longterm investment interest rate swap contract liability shortterm borrowing current portion longterm debt longterm debt financing instrument interest rate swap contract longterm investment longterm investment include noncurrent asset primarily consist debt equity security hold nonqualified trust fund longterm employee benefit obligation include liability consolidated balance sheet asset fund relate liability longterm investment primarily classify available sale carry fair value realize gain sale security classify available sale proceed sale total respectively realize gain record income expense net interest rate swap contract asset hedge variable rate risk associate variable rate time deposit purchase company enter interest rate swap mature november term swap company receive fix rate approximately percent pay threemonth libor rate notional swap designate cash flow hedge effective portion swap defer transaction hedge record earning interest rate swap maturity value swap fair value december table content liability company utilize interest rate swap international cash management strategy notional principal arrangement notional principal arrangement arrangement year term december arrangement provide payment interest base libor receipt interest base annual election float rate result company remain subject moderate degree market risk maturity swap swap designate hedge instrument accordingly change fair value record earning annual net cash flow payment receipt interest rate swap contract material net asset liability interest rate swap record current asset accrue liability applicable fair value swap liability december company trigger credit rating downgrade provision swap arrangement result counterparty terminate swap impact terminate swap material borrowing general shortterm borrowing consist commercial paper issue united states bank loan note payable connection company purchase research office facility company issue note pay march impute interest rate note percent commercial paper outstanding december respectively weightedaverage interest rate shortterm borrowing december percent percent respectively november company issue aggregate principal percent senior unsecured note aggregate principal percent senior unsecured note interest payable semiannually net proceed offer issuance note rate moodys investors service inc moodys creditwatch negative implication standard poor rating service interest rate payable note subject adjustment follow rate assign note moodys change rating set forth interest rate payable series note increase additional interest rate set forth similarly rate assign note change rating set forth interest rate payable series note increase additional interest rate set forth additional interest rate moodys rating rating baa bbb baa bbb baa bbb event interest rate note increase percent initial coupon rate percent percent respectively moodys table content subsequently upgrade rating interest rate correspondingly reduce percent percent respectively furthermore interest rate payable particular series note return percent percent respectively rate adjustment provision permanently cease apply follow downgrade moodys respectively moodys raise rating respectively well note redeemable company option time redemption price equal great percent principal note sum present value remain schedule payment principal interest discount rate treasury note comparable remain term plus basis point note basis point note fair value combine note december company revolve credit facility total recently negotiate facility september day credit facility major financial institution draw united states facility mature september facilities syndicate financial institution provide draw united states repayment second multicurrency facility draw united states internationally maturity date facility available general corporate purpose consider support company commercial paper borrowing facility require compensating balance nominal commitment fee pay december fund draw facility addition company foreign subsidiary approximately available unused line credit financial institution december credit rating change credit rating december lower company corporate credit longterm debt rating say outlook rating negative note weakening company intron franchise expect decline earning cash flow change company shortterm corporate credit commercial paper rating lower july january place company corporate credit rating shortterm credit rating senior unsecured debt rating creditwatch negative implication february downgrade company senior unsecured debt rating time lower company shortterm corporate credit commercial paper rating remove company creditwatch outlook remain negative october moodys lower company corporate credit rating lower commercial paper rating follow rating action moodys remove company watchlist revise rating outlook stable negative moodys state credit rating assume modest outflow settle outstanding litigation acquisition large payment associate litigation proceeding acquisition activity place pressure rating andor outlook november fitch rating fitch downgrade company senior unsecured bank loan rating commercial paper rating table content company rating outlook remain negative announce downgrade fitch note sale decline company lead product franchise intron franchise greater anticipate concerned total company growth reliant performance key growth driver zetia remicade near term table content finance instrument subsidiary company issue equitytype security security certain feature feature obligation include longterm liability december securities bore liborbase yield substantially fix november december rate percent company exercise option fully redeem security november commitment total rent expense amount future minimum rental commitment noncancelable operating lease december range aggregate minimum lease obligation december company commitment total related capital expenditure insurance coverage company maintain insurance coverage deductible selfinsurance management believe adequate need current circumstance coverage reflect market condition include cost availability exist time write relationship insurance coverage selfinsurance vary accordingly result recent external event availability insurance restrictive management consider impact change continually assess good way provide insurance need future company selfinsure high proportion risk past especially relate product liability income expense net component income expense net follow interest cost incur capitalize construction interest expense interest income foreign exchange gain loss net total net include gain sale marketing right suboxone subutex cash pay interest net amount capitalize respectively table content shareholder equity summary treasury share transaction follow share millions share balance january share issue stock incentive plan purchase treasury share share balance december company prefer share purchase right outstanding attach presently trade company common share exercisable right exercisable person group acquire percent company common stock announce tender offer complete result ownership person group percent company common stock person group acquire percent company outstanding common stock merger business combination transaction right entitle holder acquirer purchase common share scheringplough market value twice exercise price right exercise price right follow acquisition person group beneficial ownership percent percent company common stock board director exchange right right own acquirer exchange ratio common share hundredth share series junior participate prefer stock right prior acquisition person group beneficial ownership percent company common stock right redeemable right option board director right expire july early redeem exchange board director authorize reduce percent threshold refer great sum percent large percentage outstanding share common stock know company beneficially own person group affiliate associate person percent follow acquisition person group beneficial ownership percent company common stock reduction adversely affect interest holder right equity income cholesterol joint venture company merck inc merck agreement jointly develop market zetia ezetimibe oncedaily monotherapy coadministration zetia statins ezetimibe oncedaily fixedcombination tablet simvastatin zocor merck cholesterolmodifye medicine agreement involve development marketing oncedaily fixedcombination tablet contain claritin singulair singulair merck oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis january scheringploughmerck pharmaceutical report result phase iii clinical trial fixedcombination tablet contain claritin singulair demonstrate sufficient add benefit treatment seasonal allergic rhinitis agreement generally provide equal sharing development cost copromotion approve product company united states country world japan japan agreement exist general copromotion provide table content company provide equal physician marketing effort company bear cost sale force marketing product general agreement provide venture operate virtual mode maximum degree possible rely respective infrastructure company company agree share certain cost cost limited portion cost manufacturing cost specialty sale force certain specially identify promotion cost note company incur substantial cost sell cost reflect equity income cholesterol joint venture bear entirely company agreement provide jointly own facility product result collaboration manufacture facility own merck company company earn milestone relate certain european approval zetia certain condition merck pay additional milestone company total prior venture research development phase company share research development expense respectively report research development statement consolidated operation venture move research development phase zetia launch late marketing application combination ezetimibesimvastatin submit fda september reflect venture year commercial operation company adopt equity method account effective beginning method company record share operating profit share research development cost equity income cholesterol joint venture statement consolidated operation prior year amount affect equity income cholesterol joint venture year end december include company share operating profit milestone receipt share research development cost stock incentive plan term company stock incentive plan approve company shareholder million company common share grant stock option award deferred stock unit officer certain employee company december december million option defer stock unit remain available future year grant stock incentive plan option exercise price equal market price common share grant date option expire later year date grant standard option grant prior generally year vest term option grant vest long period range year defer stock unit payable equivalent number common share share distributable single installment equal annual installment generally commence year date award table content follow table summarize stock option activity past year current prior plan approve company shareholder weight weight weight number average number average number average exercise exercise exercise number option million option price option price option price outstanding january grant exercise cancel expire outstanding december exercisable december summarize information stock option outstanding exercisable december follow number option million outstanding exercisable weighted average weighted weight number remain average number average term exercise exercise exercise price range option year price option price company award defer stock unit total million million million respectively inventory yearend inventory consist follow finished product good process raw material supply total inventory inventory value lastin firstout basis comprise approximately percent percent total inventory december respectively estimate replacement cost total inventory december respectively retirement plan postretirement benefit company define benefit pension plan cover eligible employee united states certain foreign country company provide post retirement health care benefit eligible retiree dependent measurement date majority plan december table content net pension expense compare net pension expense increase principally cost associate voluntary early retirement program special charge footnote additional information estimate onehalf percent reduction expect long term rate return consolidate plan asset increase pension expense approximately estimate onehalf percent reduction discount rate increase pension expense approximately december company unrecognize net pension loss gain loss arise primarily plan asset earn longterm expect rate return change pension discount rate gain future offset net unrecognized loss amortization loss ultimately increase annual pension expense approximately component net pension postretirement benefit expense income follow postretirement retirement plan health care benefit service cost interest cost expect return plan asset amortization net termination benefit curtailment settlement net pension postretirement benefit expense income component change benefit obligation follow postretirement retirement plan health care benefit benefit obligation january service cost interest cost assumption change effect exchange rate change benefit pay actuarial loss plan amendment termination benefit curtailment settlement benefit obligation december benefit obligation overfunde plan benefit obligation underfunde plan termination benefit curtailment settlement cost primarily relate matter discuss special charge footnote table content component change plan asset follow postretirement retirement plan health care benefit fair value plan asset primarily stock bond january actual gain loss plan asset contribution effect exchange rate change benefit pay fair value plan asset december plan asset overfunde plan plan asset underfunde plan fair value plan asset domestic pension plan december respectively addition plan asset indicate december security respectively hold nonqualified trust designate provide pension benefit certain underfunde plan december accumulate benefit obligation retirement plan respectively aggregate accumulate benefit obligation fair value plan asset retirement plan accumulate benefit obligation excess plan asset respectively december respectively december presently company anticipate make contribution fund retirement plan postretirement health care plan follow reconciliation fund status plan company balance sheet postretirement health retirement plan care benefit benefit obligation excess plan asset unrecognize net transition asset unrecognize prior service cost unrecognize net actuarial loss net asset december amount recognize balance sheet consist postretirement health retirement plan care benefit prepay benefit cost accrue benefit cost intangible asset accumulate comprehensive income net asset december table content company recognize additional minimum pension liability respectively primarily relate domestic retirement plan result adjustment accumulate comprehensive income net tax respectively consolidated weightedaverage assumption determine benefit obligation december postretirement retirement plan health care benefit discount rate rate increase future compensation consolidated weightedaverage assumption determine net cost year end december postretirement retirement plan health care benefit discount rate longterm expect rate return plan asset rate increase future compensation longterm expect rate return plan asset domestic retirement plan percent percent year end december respectively longterm expect rate return plan asset derive proportionally return assumption determine major asset class principally equities fix income real estate return expectation asset class base largely assumption economic growth inflation support longterm historical data weightedaverage assume health care cost inflation rate postretirement measurement purpose percent trend percent percent increase assume health care cost trend rate increase combined postretirement service interest cost postretirement benefit obligation percent decrease assume health care cost trend rate decrease combined postretirement service interest cost postretirement benefit obligation medicare prescription drug improvement modernization act act sign law united states company elect defer accounting effect act permit fasb staff position fas benefit obligation report company postretirement benefit plan reflect impact act specific authoritative guidance account federal subsidy relate act pende issue require company change previously report information table content plan asset fair value asset allocation retirement plan december target allocation follow percentage plan target asset december allocation asset category equity security debt security real estate total asset allocation postretirement health care benefit trust december target allocation follow percentage plan target asset december allocation asset category equity security debt security total company investment relate plan broadly diversify consist primarily equity fix income security objective generate longterm investment return consistent acceptable level overall portfolio market value risk company define contribution profitshare plan cover substantially fulltime domestic employee complete year service annual contribution determine formula base company income shareholder equity participant compensation profitshare expense total respectively profit sharing contribution determine formula describe company long contribution plan effective income taxis foreign operation contribute income income taxis follow united states foreign total lossincome income taxis table content component income tax expensebenefit follow current federal foreign state total current deferred federal state foreign total defer total income tax expense difference income taxis base statutory tax rate company income tax expense follow income tax expensebenefit statutory tax rate increase decrease taxis result low rate jurisdiction net nondeductible litigation reserve reserve tax litigation research tax credit state income tax permanent difference net income tax expense effective tax rate low rate jurisdiction net primarily attributable certain employment capital investment action take company result income manufacturing activity jurisdiction subject low tax rate tax loss company record tax refund receivable december december company total defer tax asset respectively defer tax liability respectively valuation allowance december valuation allowance significant december significant defer tax asset december operating cost employee termination cost currently deductible tax purpose total respectively significant defer tax liability december depreciation difference respectively retirement plan respectively defer taxis provide undistributed earning foreign subsidiary consider permanent investment december approximate determine tax liability arise earning remit practicable table content net consolidated income tax payment respectively december internal revenue service irs complete examination company tax return year unresolved issue outstanding year irs examination year expect complete time anticipate irs commence examination year legal environmental regulatory matter footnote tax matter company believe litigation probable consent decree company announce reach agreement fda consent decree resolve issue involve company compliance current good manufacturing practice cgmp certain manufacturing facility new jersey puerto rico district court district new jersey approve enter consent decree term consent decree company agree pay total government equal installment installment pay second installment pay previously report company accrue provision consent decree fourth quarter consent decree require company complete number action event certain action agree consent decree satisfactorily complete time fda assess payment deadline miss consent decree require company develop submit fdas concurrence comprehensive cgmp work plan company manufacture facility new jersey puerto rico cover decree company receive fda concurrence propose cgmp work plan cgmp work plan contain number significant step timely satisfactory completion subject payment thousand business day deadline miss payment exceed year payment subject overall cap connection discussion fda company cgmp work plan pursuant term decree company fda enter letter agreement date april letter agreement company fda agree extend month time period company incur payment describe respect certain significant step propose date december letter agreement increase yearly overall cap payment describe addition decree require company complete program revalidation finish drug product bulk active pharmaceutical ingredient manufacture covered manufacturing facility company require consent decree complete revalidation program bulk active pharmaceutical ingredient september finish drug december general timely satisfactory completion revalidation subject payment thousand business day deadline miss subject cap describe product schedule revalidation certify validate date validation schedule fda table content assess payment percent net domestic sale uncertified product validation certify general product schedule revalidation consent decree certify month schedule date company cease production product certification obtain completion significant step work plan completion revalidation program subject thirdparty expert certification accept fda consent decree provide company believe able meet deadline company right show good cause request extension deadline connection cgmp work plan revalidation program guarantee fda grant request company believe significant progress meet obligation consent decree possible company fail complete significant step revalidation prescribe deadline party expert certify completion significant step revalidation fda disagree expert certification significant step revalidation case possible fda assess payment describe company expense payment assess decree incur note legal environmental regulatory matter footnote company receive notice false claim complaint bring individual purport act behalf government approximately pharmaceutical company allege pharmaceutical company defraud united states sale federal governmental agency drug allegedly manufacture manner comply current good manufacturing practice company defendant file motion dismiss action segment information company reportable segment prescription pharmaceutical consumer health care animal health segment sale profit datum follow consistent company current management reporting structure establish second quarter prior period information present restate comparable basis prescription pharmaceutical segment discover develop manufacture market human ethical pharmaceutical product consumer health care segment develop manufacture market otc foot care sun care product animal health segment discover develop manufacture market animal health product net sale segment year end december prescription pharmaceutical consumer health care animal health consolidate net sale table content profit segment year end december prescription pharmaceutical consumer health care animal health corporate consolidated lossprofit tax corporate include charge relate voluntary early retirement program special charge footnote additional information estimate charge relate reportable segment follow prescription pharmaceutical consumer health care animal health corporate corporate include provision increase litigation reserve asset impairment charge interest income expense foreign exchange gain loss headquarters expense miscellaneous item accounting policy segment report describe summary significant accounting policy net sale major therapeutic category antiinfective anticancer allergy respiratory cardiovascular dermatological pharmaceutical prescription pharmaceutical otc include otc claritin sale respectively foot care sun care consumer health care animal health consolidate net sale company subsidiary country outside united states sale outside united states comprise percent consolidated net sale percent percent single foreign country france japan italy account percent consolidated net sale past year france account percent percent percent consolidate net sale respectively japan account percent percent percent consolidate net sale respectively italy account percent percent percent consolidate net sale respectively table content net sale geographic area united states europe canada latin america pacific area asia consolidate net sale net sale present geographic area company customer locate percent percent percent respectively consolidated net sale mckesson corporation major pharmaceutical health care product distributor percent percent percent respectively consolidated net sale amerisourcebergen corporation major pharmaceutical health care product distributor longlive asset geographic location united states ireland singapore puerto rico total longlive asset show geographic location primarily property sale product comprise percent company international sale year end december follow international intron franchise clarinex otc claritin remicade company disaggregate asset segment basis internal management report information present table content legal environmental regulatory matter background company responsibility environmental cleanup state local federal law include comprehensive environmental response compensation liability act commonly know superfund superfund site equivalent site state law company allege potentially responsible party prp company estimate obligation cleanup cost superfund site base information obtain federal environmental protection agency epa equivalent state agency andor study prepare independent engineer probable cost pay prps company record liability environmental assessment andor cleanup probable loss incur reasonably estimate company involve claim legal proceeding nature consider normal business include product liability case company adjust accrue liability reflect current good estimate probable loss exposure good estimate determinable company accrue minimum probable range liability record liability matter december relate expense incur month end december material expect insurance recovery consider determine cost environmentalrelate liability management believe matter discuss remainder section remote time material liability excess amount accrue incur respect matter discuss remainder section note practicable estimate range reasonably possible loss reserve include financial statement resolution matter discuss remainder section individually aggregate material adverse effect company result operation financial condition management review status matter discuss remainder section ongoing basis time time settle resolve term condition management believe good interest company company aware settlement matter type set forth remainder section particular investigation frequently involve fine andor penalty material financial condition result operation entity enter settlement assurance company prevail matter settlement reach acceptable term include scope release provide amount exceed amount reserve acceptable settlement reach assurance investigation litigation commence raise similar type issue potentially expose company additional material liability company predict timing resolution matter outcome table content environmental resident vicinity publicly own wastewater treatment plant barceloneta puerto rico file lawsuit plant owner operator numerous company discharge plant include subsidiary company damage injunctive relief relate odor allegedly come plant connect sewer lawsuit class action claim damage trial date set case matter submit mediation november receive general notice potential liability epa address arnoscholl adhesive tape inc subsidiary company relate lake culmet cluster site chicago illinois potentially responsible party site scheringplough respond information request new jersey department environmental protection relate contamination low passaic river basin scheringplough deny connection contamination late september department direct prps contaminate site assess restore natural resource damage low passaic river basin department scheringplough prp department send scheringplough letter receive september state company legally responsible damage natural resource state department adopt regulation cover liability calculate making difficult accurately predict ultimate extent company exposure patent matter claritin patent february geneva pharmaceuticals inc geneva submit abbreviate new drug application anda fda seek market generic claritin tablet expiration company desloratadine compound patent company believe protect claritin geneva allege desloratadine compound patent invalid patent material company business march company file suit federal court seek rule genevas anda submission constitute infringement company desloratadine compound patent challenge patent merit addition geneva follow company similar anda submission generic claritin tablet zenith goldline pharmaceutical mylan pharmaceuticals inc teva pharmaceuticals usa inc teva ranbaxy pharmaceuticals inc ranbaxy genpharm incorporate perrigo company perrigo follow company similar anda submission generic claritin syrup teva copley pharmaceuticals inc novex pharma alpharma uspd inc taro pharmaceuticals usa inc morton grove pharmaceuticals inc perrigo andrx pharmaceuticals llc andrx impax laboratories inc impax similar anda submission generic claritind hour claritind hour formulation ranbaxy similar anda submission generic claritind hour formulation esi lederle inc lederle subsidiary wyeth similar anda submission generic claritin reditab formulation follow company submit paper new drug application paper nda section federal food drug cosmetic act seek market generic otc form claritin prior expiration company desloratadine compound patent whitehallrobin healthcare division wyeth otc reditab formulation mcneil consumer healthcare mcneil otc tablet perrigo otc tablet case company file suit federal court seek rule applicable anda paper nda submission propose marketing generic prescription otc product constitute infringement company desloratadine compound patent challenge table content patent merit august federal district court new jersey rule motion summary judgment find certain claim desloratadine compound patent anticipate prior patent valid august district court decision sustain appellate court october appellate court deny company petition rehear ruling action defendant infringement desloratadine compound patent manufacturer loratadine proceed company assert impaxs andrxs andas generic claritind hour formulation infringe company patent cover claritind hour formulation october company settle litigation impax andrx license patent rebetol patent august geneva pharmaceuticals technology corp geneva pharmaceuticals river pharmaceutical llc river january teva submit separate anda fda seek market generic form rebetol ribavirin capsules united states expiration company patent cover ribavirin formulation geneva pharmaceutical river teva assert infringe company rebetol patent andor patent invalid rebetol patent material company business september october march company file suit federal court seek ruling anda submission geneva pharmaceutical river teva respectively constitute infringement company patent challenge company patent merit company enter separate licensing agreement river geneva pharmaceuticals teva settle patent litigation company river teva geneva pharmaceuticals grant river geneva pharmaceuticals teva nonexclusive nonsublicensable license company ribavirin patent agreement subject dismissal river geneva pharmaceuticals tevas report patent litigation ribapharm inc subsidiary valeant pharmaceutical international ribapharm litigation dismiss defendant motion summary judgment july ribapharm appeal summary judgment decision ribapharm petitioned fda deny approval river geneva pharmaceuticals teva products fda act ribapharm petition date report prime pac prrs patent january jury find company prime pac prrs porcine respiratory reproductive syndrome vaccine infringe patent own boehringer ingelheim vetmedica inc injunction issue august bar sale company vaccine company posttrial motion reversal jurys verdict new trial deny september company appeal verdict affirm appellate court february litigation damages phase case ongoing trial determine damage schedule investigation pennsylvania investigation october company receive subpoena attorney office eastern district pennsylvania pursuant health insurance portability accountability act concern company contract pharmacy benefit manager pbms manage care organization provide disease management service connection marketing pharmaceutical product appear subpoena number address industry participant inquiry thing pharmaceutical marketing practice government inquiry focus thing company disease management marketing table content program arrangement comply federal health care law value disease management program marketing program arrangement include calculation rebate government company cooperate investigation march attorney office begin issue grand jury subpoena grand jury investigation appear focus transaction manage care organization government believe company offer provide deeply discount pharmaceutical product know nominally price product generally exclude medicaid rebate calculations free discount disease management service marketing program arrangement deliver value order place retain company major pharmaceutical product manage care organization formulary grand jury appear investigate thing transaction describe conduct relate thereto violate federal antikickback statute value item service describe include company calculation medicaid rebate outcome investigation include commencement civil andor criminal proceeding involve substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program company predict investigation affect marketing practice sale quarter company increase litigation reserve relate investigation investigation describe attorney office district massachusetts increase reserve reflect mature discussion office particularly eastern district pennsylvania adjustment company estimate minimum liability relate investigation compliance generally accept accounting principle gaap gaap company require estimate recognize minimum liability loss probable well estimate loss fourth quarter company increase litigation reserve matter company predict timing resolution matter company note total reserve reflect estimate final settlement adjudication matter possibly materially exceed aggregate liability accrue company materially adverse effect operation financial condition company awp investigation company respond investigation department health human services department justice committee energy commerce house representatives certain state certain industry company practice average wholesale price awp investigation include department justice review merit federal action file private entity behalf united states district court southern district florida investigation attorney office district massachusett inter alia awp set pharmaceutical company certain drug improperly exceed average price pay dispenser consequence result unlawful inflation certain government drug reimbursement base awp march company receive subpoena massachusetts attorney general office seek document concern use awp pricing andor marketing practice company cooperate investigation outcome investigation include imposition substantial fine penalty injunctive administrative remedy massachusetts investigation attorney office district massachusetts investigate company sale product manufacture private label arrangement manage care organization include company medicaid good price calculation early november company serve table content additional grand jury subpoena attorney district massachusetts information subpoena seek broad range information concern company sale marketing clinical trial practice program respect intron rebetron temodar company sale marketing contact manage care organization doctor company offer provision grant honorarium item service value manage care organization physician group doctor educational institution company understand investigation focus certain sale marketing clinical trial practice conduct relate thereto certain instance relate use mention product indication fda approval obtain socalle offlabel use violation federal law regulation respect offlabel promotional activity investigation appear focus drug sample clinical trial grant item service value give provider incentivize prescribe abovementione product include offlabel use violation federal health care antikickback law company implement certain change sale marketing clinical trial practice continue review practice ensure compliance relevant law regulation company cooperate investigation future sale intron rebetron temodar adversely affect company time predict ultimate impact sale outcome investigation include commencement civil andor criminal proceeding involve imposition substantial fine penalty injunctive administrative remedy include exclusion government reimbursement program quarter company increase litigation reserve relate investigation attorney office district massachusetts describe paragraph paragraph immediately precede investigation describe attorney office eastern district pennsylvania increase litigation reserve reflect adjustment company estimate minimum liability relate investigation compliance gaap gaap company require estimate recognize minimum liability loss probable well estimate loss fourth quarter company increase litigation reserve matter company note total reserve reflect estimate final settlement adjudication matter possibly materially exceed aggregate liability accrue company materially adverse effect operation financial condition company company predict timing resolution matter outcome report file scheringplough disclose connection abovedescribe investigation attorney office district massachusetts sale marketing clinical trial practice matter schere corporation wholly own significant operating subsidiary scheringplough receive letter boston target letter office advise schering corporation include subsidiary division target federal criminal investigation respect area provide remuneration drug sample clinical trial grant item service value manage care organization physician induce purchase schering pharmaceutical product payment federal health care program table content sale misbrande unapproved drug company understand mean drug promote indication approval fda obtain socalle offlabel use submit false pharmaceutical pricing information government purpose calculate rebate require pay medicaid program fail include price product repackage arrangement manage care customer price free nominally price good provide customer induce purchase schering product document destruction obstruction justice relate government investigation target define department justice guideline person prosecutor grand jury substantial evidence link commission crime judgment prosecutor putative defendant attorney manual section consumer product matter department justice antitrust division investigate company consumer product division enter agreement company low commission rate consumer product broker february antitrust division serve grand jury subpoena company seek document time company cooperate investigation nitrodur investigation august company receive civil investigative subpoena issue office inspector general department health human service seek document concern company classification nitrodur medicaid rebate purpose company use nominal pricing bundle product sale company cooperate investigation appear subpoena number address pharmaceutical company concern inquiry issue relate payment government rebate security class action litigation february company state press release fda conduct inspection company manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current good manufacturing practice primarily relate production process control procedure day february lawsuit file district court district new jersey company certain name officer allege violation section securities exchange act rule promulgate thereunder additional lawsuit tenor follow complaint consolidate action district court district new jersey lead plaintiff florida state board administration appoint court july october consolidated amend complaint file allege violation describe second sentence paragraph purport represent class shareholder purchase share company stock february companys motion dismiss consolidated amend complaint deny october court certify shareholder class discovery ongoing addition lawsuit describe immediately precede paragraph lawsuit file district court district new jersey lawsuit file new table content jersey state court company nominal defendant certain officer director director seek damage behalf company include disgorgement trading profit defendant allegedly obtain basis material nonpublic information complaint lawsuit relate issue describe company february press release allege failure disclose material information breach fiduciary duty director federal court lawsuit include allegation relate investigation attorney office eastern district pennsylvania district massachusetts ftcs administrative proceeding company lawsuit state texas warrick pharmaceuticals warrick companys generics subsidiary describe lawsuit shareholder derivative action purport assert claim behalf company demand board director decision company pursue claim august plaintiffs new jersey state court shareholder derivative action move dismiss voluntarily complaint action motion grant shareholder derivative action pende district court district new jersey consolidate action early stage january company receive demand letter date december law firm involve derivative action describe behalf shareholder involve derivative action demand board director bring claim behalf company base allegation substantially similar allege derivative action january board director adopt board resolution establish evaluation committee consist director investigate review analyze fact circumstance surround allegation demand letter consolidate amend derivative action complaint describe reserve board authority discretion exercise business judgment respect proper disposition demand committee engage independent outside counsel advise issue report finding investigation independent director board late october report determine shareholder demand refuse find liability officer director november board adopt recommendation evaluation committee august prescription access litigation project pal bostonbased group form litigate drug company issue press release state pal member file lawsuit new jersey state court company december company serve amend complaint case suit pal purport class action allege thing company directtoconsumer advertising falsely depict benefit claritin violation new jersey consumer fraud act february company file motion dismiss case court dismiss complaint entirety failure state claim plaintiff appeal deny new jersey state court plaintiff request new jersey supreme court hear case request deny end litigation company defendant number purport nationwide state class action lawsuit plaintiff seek refund purchase price laxative phenylpropanolaminecontaine coughcold remedy ppa product purchase pharmaceutical manufacturer codefendant lawsuit general plaintiff claim purchase pay product know certain defect medical risk attendant use litigation claim relate company ppa product court national class action suit state class action table content suit deny certification dismiss suit similar application dismiss new jersey remain statewide class action suit involve company pende approximately individual lawsuit relate laxative product ppa product recall albuterolvancerilvancenase inhaler pende company seek recovery personal injury death number lawsuit punitive damage claim march company serve putative class action complaint file district court new jersey allege company richard jay kogan resign chairman board november retire chief executive officer president director company april companys employee saving plan plan administrator breach fiduciary obligation certain participant plan allegation primarily relate disclosure companys good manufacturing practice issue discuss early security class action litigation section relation company disclosure consent decree fda relate matter disclosure meeting investor week september communication discuss sec inquiry relate litigation company serve second putative class action complaint file court allegation nearly identical complaint file march october consolidated amend complaint file name additional defendant follow director eugene mcgrath donald miller carl mundy patricia russo kathryn turner director james wood regina herzlinger corporate officer consolidate amend complaint contain allegation associate boston target letter describe investigation section footnote company file motion dismiss complaint august lawsuit file new jersey superior court chancery division union county serve company nominal defendant company outside director allege breach fiduciary duty director relate company receipt boston target letter describe investigation section footnote action temporarily stay pende adjudication separate relate action frame shareholder request access company book record seek document information relate massachusetts investigation antitrust ftc matter company defendant numerous antitrust action commence start state federal court independent retail pharmacy chain retail pharmacy consumer plaintiff allege price discrimination andor conspiracy company defendant restrain trade jointly refuse sell prescription drug discount price plaintiff company february agree settle federal class action behalf approximately twothird retail pharmacy united states total pay district court illinois approve settlement federal class action seventh circuit court appeal dismiss appeal settlement subject review april certain plaintiff federal class action commence purport class action district court illinois company defendant settle previous federal class action complaint allege defendant conspire implement settlement commitment follow settlement discuss district court deny plaintiff motion preliminary injunction hearing table content company settle dismiss motion state court retailer consumer action settlement amount material company federal court illinois remand conspiracy portion case retailer opt class action district court file case consolidate federal district court brooklyn new york federal court illinois jurisdiction robinson patman portion case trial conspiracy claim set begin october plaintiffs antitrust action generally seek treble damage unspecified injunction allegedly unlawful conduct april ftc start administrative proceeding company upshersmith inc upshersmith lederle complaint allege anti competitive effect settlement patent lawsuit company lederle company upshersmith lawsuit settle related generic version kdur company longacte potassium chloride product subject andas file lederle upshersmith june administrative law judge oversee case issue decision patent litigation settlement comply law respect dismiss claim company appeal decision commission file ftc staff december commission issue opinion reverse decision administrative law judge find violation antitrust law rule instead company settlement fact violate law ftcs decision involve monetary penalty company appeal decision federal court appeal kdur potassium chloride supplement cardiac patient follow commencement ftc administrative proceeding allege class action suit file behalf direct indirect purchaser kdur company upshersmith lederle federal state court suit allege essentially fact claim violation federal state antitrust law state statutory andor common law cause action motion dismiss action pende pricing matter quarter warrick pharmaceuticals warrick companys generics subsidiary sue state texas june company subsidiary schering corporation add defendant lawsuit allege warrick supply state false report wholesale price cause state pay medicaid claim prescription warrick albuterol sulfate solution inhaler higherthanjustifie level state seek damage approximately warrick include treble damage penalty trial date april set outcome litigation result imposition fine penalty injunctive remedy case go trial assurance damage seek state exceed set forth state petition december pal file class action suit federal court massachusetts company september consolidated complaint file court result coordination multidistrict litigation panel federal court awp case country consolidate complaint allege company warrick conspire provider defraud consumer report fraudulently high awps table content prescription medication reimburse medicare thirdparty payer complaint seek declaratory judgment unspecified damage include treble damage include pal litigation describe prior paragraph lawsuit allege company warrick report inflated awps prescription pharmaceutical cause state federal entity thirdparty payer excess reimbursement provider action allege company warrick fail report accurate price medicaid rebate program underpaid rebate state action begin october bring state attorney general private plaintiff nonprofit organization employee benefit fund allege violation federal state law include fraud antitrust racketeer influence corrupt organization act rico claim addition warrick company defendant number lawsuit state court action generally bring states andor political subdivision seek unspecified damage include treble punitive damage sec inquiry relate litigation sec investigate compliance polish subsidiary certain pharmaceutical company foreign corrupt practice act pursuant order date november company voluntarily produce document relate polish subsidiary subsidiary country company continue cooperate sec request company cooperate inquiry police katowice poland ask related information september sec company announce settlement sec enforcement proceeding company richard jay kogan chairman chief executive officer meeting hold investor week september communication admit deny allegation company agree commit future violation regulation relate security law pay civil penalty million kogan pay civil penalty thousand federal putative class action file company kogan meeting hold investor week september communication consolidate pursuant consolidation amend complaint date march file allege violation section securities exchange act relate alleged disclosure meeting mention paragraph company file motion dismiss class action plaintiff seek leave court file second amend complaint october company move dismiss second amend complaint september lawsuit file new jersey superior court union county richard jay kogan company outside director allege breach fiduciary duty fraud deceit negligent misrepresentation relate alleged disclosure meeting mention company remove case federal court motion remand state court pende matter company subject pharmacovigilance reporting requirement country jurisdiction include united states european union member states requirement differ jurisdiction jurisdiction include requirement table content report adverse event occur patient particular drug order alert manufacturer drug governmental agency potential problem pharmacovigilance inspection official british french medicine agency conduct request european agency evaluation medicinal product emea deficiency report process identify company take urgent action rectify deficiency quickly possible company know action emea national authority response finding possible action include inspection demand improvement report system criminal sanction company andor responsible individual change condition marketing authorization company product april company receive notice false claim act complaint bring individual purport act behalf government approximately pharmaceutical company district court northern district texas complaint allege pharmaceutical company include company defraud united states sale federal governmental agency drug allegedly manufacture manner comply current good manufacturing practice company defendant file motion dismiss action july tax matter october irs auditor assert report company liable additional tax tax year report allege interest rate swap company enter unrelated party recharacterize loan affiliate company result additional tax income tax seek irs auditor relate recharacterization approximately plus interest depend court company choose litigate case require pay tax possibly interest prior litigation company estimate interest approximately company prevail litigation amount pay prior litigation return company plus accrued interest company choose litigate case court require payment tax interest prior litigation management believe probable matter litigate management believe tax reserve sufficient absorb loss result unfavorable outcome litigation table content independent auditor report board director shareholder scheringplough corporation audit accompany consolidated balance sheet scheringplough corporation subsidiary december relate consolidated statement operation shareholder equity cash flow year period end december audits include financial statement schedule list item financial statement financial statement schedule responsibility corporation management responsibility express opinion financial statement financial statement schedule base audit conduct audits accordance auditing standard generally accept united states america standards require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position scheringplough corporation subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion financial statement schedule consider relation basic consolidated financial statement take present fairly material respect information set forth sdeloitte touche llp parsippany new jersey february table content scheringplough corporation subsidiary quarterly datum unaudite month end march june september december dollar million share figure net sale cost sale gross profit sell general administrative research development income expense net special charge equity incomeloss cholesterol joint venture lossincome income taxis income tax benefitexpense net lossincome dilute lossearning common share basic lossearning common share dividend common share common share price high low average share outstanding diluted eps million average share outstanding basic eps million effective company present collaboration merck inc merck follow equity method accounting method company record share operating profit share research development cost equity incomeloss cholesterol joint venture operating profit venture include net sale alliance revenue quarter reclassify equity incomeloss cholesterol joint venture company share venture research development cost report research development previous quarter reclassify equity incomeloss cholesterol joint venture second quarter company earn milestone merck report income expense net second quarter reclassify equity incomeloss cholesterol joint venture prior year affect new presentation equity income cholesterol joint venture footnote note consolidated financial statement additional information special charge footnote note consolidated financial statement additional information relate special charge table content cost sale fourth quarter include favorable adjustment reflect settlement arbitration relate thing royalty payment biogen year impact material fourth quarter adjustment partially offset relate accrual previous quarter income expense net fourth quarter include gain sale marketing right suboxone subutex company common share list principally trade new york stock exchange approximate number holder record common share january table content item change disagreement accountant account financial disclosure applicable item control procedure management include chief executive officer chief financial officer evaluate company disclosure control procedure end period cover conclude company disclosure control procedure effective conclude change companys internal control financial reporting occur company recent fiscal quarter materially affect reasonably likely materially affect company internal control financial reporting iii item director executive officer registrant information concern director nominee director set forth caption election director stock ownership company proxy statement annual meeting shareholder april incorporate reference information require executive officer include file caption executive officer registrant company board director determine company audit committee financial expert serve audit committee financial expert arthur weinbach independent define new york stock exchange list standard restrictive scheringplough board independence standard find scheringplough corporate governance guideline available web site include proxy statement require rule securities exchange act amend company adopt code ethic senior financial officer apply company chief executive officer chief financial officer controller code ethic senior financial officer file exhibit write copy code ethic senior financial officer business conduct policy employee director code conduct ethic provide charge write corporate secretary scheringplough corporation gallop hill road mail stop kenilworth new jersey code ethic senior financial officer business conduct policy employee director code conduct ethic available scheringplough web site httpphxcorporateirnetphoenixzhtmlcpirolgovconduct table content item executive compensation executive compensation information set forth caption executive compensation company proxy statement annual meeting shareholder april incorporate reference item security ownership certain beneficial owner management relate stockholder matter information concern security ownership certain beneficial owner management set forth caption stock ownership company proxy statement annual meeting shareholder april incorporate reference equity compensation plan information follow information relate plan equity security company issue employee director company plan equity security issue nonemployee stock incentive plan predecessor plan certain stock option transferable family member employeeoptionee relate trust column column number security number security column remain available future issue weightedaverage issuance equity exercise exercise price compensation plan outstanding option outstanding option exclude security plan category warrant right warrant right reflect column equity compensation plan approve security holder stock incentive plan predecessor plan equity compensation plan approve security holder director stock award plan scheringplough ireland share purchase scheme nonplan inducement award approve security restrict holder share total table content plan provide annual grant share common stock nonemployee director director defer award stock unit pay share common stock deferral period end plan permit employee reside ireland enjoy tax advantage christmas bonus pay pass trustee trustee purchase share common stock open market allocate share employee account irish pound employee defer year employee sell withdraw share allocate account year represents restrict share award pursuant restrict share agreement outside equity compensation plan adopt company hassan award restricted share commencement employment april cox award restricted share commencement employment award restrict share vest anniversary award date nonplan award authorize compensation committee board approve stockholders company item certain relationship relate transaction information concern certain relationship relate transaction set forth caption certain transaction companys proxy statement annual meeting shareholder april incorporate reference item principal accountant fee service information concern principal accountant fee service set forth caption ratification designation independent auditor company proxy statement annual meeting shareholder april incorporate reference table content item